

# Index

## A

- A-74704, 486–8  
A-77003, 487–9  
A-78791, 488–9  
A-80987, 488–9  
A-83962, 488–9  
*ab initio* quantum mechanics, 337–8  
abacavir, 478–9, 481, 717, 732  
abatacept, 266  
Abbott pharmaceuticals, 12, 485  
abciximab, 140, 717  
abdominal infections, treatment of, 443  
abdominal muscles, relaxation, 591  
Abelson tyrosine kinase inhibitors, 552–5  
abiraterone, 538, 717, 732  
ABT 378, 488  
ABT 538, 488  
abzymes, 572  
7-ACA; see 7-aminocephalosporinic acid  
ACE; See angiotensin-converting enzyme  
acebutolol, 624–6, 717, 732  
acetaldehyde, 208  
acetorphan, 653, 717  
acetyl coenzyme A, 162, 580–1  
acetylation  
  aspirin synthesis, 285–6  
  by aspirin, 222  
  drug metabolism, 162, 166  
  histone acetylase, 564  
  of proteins, 25  
N-acetylation, 25  
acetylcholine, 42–4, 578–88, 609, 712,  
  see also acetylcholinesterase,  
  anticholinesterases, cholinergic  
  agonists, cholinergic antagonists, and  
  cholinergic receptors  
  active conformation, 584  
  binding interactions with cholinergic  
  binding site, 368, 583  
  biosynthesis, 580–1  
  control of gastric acid release, 659–60  
  hydrolysis by acetylcholinesterase, 595–7  
  interaction with presynaptic receptors,  
  580, 613  
  pharmacophore, 585  
  role in depression, 700  
acetylcholinesterase, 96, 243–4, 390, 580,  
  595–8  
acetylcholinesterase inhibitor, 244  
N-acetylcysteine, 528  
N-acetylglucosamine, 423, 445  
L- $\alpha$ -acetylmetadol, 644  
3-acetylmorphine, 634  
6-acetylmorphine, 633–4, 637  
N-acetylmuramic acid, 423, 445  
N-acetylneuraminic acid, see sialic acid  
acetylsalicylic acid, 286, see also aspirin  
aciclovir, 95, 129–30, 472–3, 475, 573,  
  717, 732  
  prodrugs, 473  
aciclovir triphosphate, 130, 472  
Aclacin, 722  
aclacinomycin A, See aclarubicin  
Aclaplastin, 722  
aclarubicin, 563, 717  
acne, treatment of, 454, 457  
acquired immune deficiency  
  syndrome, 170, 413, 468, 471, 476; see  
  also HIV  
  appetite stimulation in patients, 206  
  clinical trials of HIV drugs, 278–9  
  patient susceptibility to *Pseudomonas*  
  *aeruginosa*, 426  
  treatment, 133, 143, 477, 479, 481  
  treatment of other diseases in AIDS  
  patients, 419, 462, 475  
  vaccination, 470  
acquired resistance, 523  
*Acremonium chrysogenum*, 436  
acrolein, 528, 530  
acromegaly, treatment of, 267  
actimid, 565  
actinomycin D, See dactinomycin  
*Actinoplanes teichomyceticus*, 448  
action potentials, 196, 714  
Actiq, 722  
activation energy, 30  
active conformation, 227, 239, 352–4,  
  401, 403  
  acetylcholine, 584  
  captopril, 354  
  cimetidine, 673–4  
  decamethonium, 353  
  kinases, 549  
  muscarine, 585  
  receptors, 112  
  serotonin antagonists, 702  
  tubulin polymerization inhibitors, 405  
active principle, 199, 328  
active site, 23, 31–3  
  acetylcholinesterase, 596–7  
  angiotensin-converting enzyme, 294–6  
  carboxypeptidase, 293  
  epidermal growth factor receptor, 549  
  neuraminidase, 499  
  thymidylate synthase, 408  
acupuncture, 649  
acute bacterial skin infections, treatment  
  of, 442  
acute myeloid leukaemia, treatment of,  
  571  
acyclovir. See aciclovir  
acyl CoA synthetase, 165  
acylases, see penicillin acylase  
acylating agent, 222  
N-acylsulfonamide, bio-isostere for  
  carboxylic acid, 236  
N-acyltransferase, 166  
Adagen, 722  
adalimumab, 268, 717  
adamanolol, 140–1  
adamantanes, 498  
ADAPT, see antibody-directed abzyme  
  prodrug therapy  
Adcetris, 722  
addiction, 1–2, 266, see also drug addiction  
Addison's disease, 690  
adefovir dipivoxil, 479, 481, 717, 732  
adenine, 71–2  
  binding interactions, 224  
  nucleophilic groups, 124  
adenosine, 36, 44, 51, 535  
adenosine deaminase, 96, 267, 534–5  
  inhibitors, 535  
adenosine 5'-diphosphate, 55  
adenosine 5'-monophosphate, 36–7  
adenosine receptors, 56  
adenosine 5'-triphosphate, 54–5, 60–1,  
  548–9, 551, 580, 612–13, 680  
S-adenosyl methionine, 162, 166  
S-adenosylhomocysteine hydrolase, 510  
adenovirus, 573  
adenylate cyclase, 59–64  
adenylyl cyclase, see adenylyl cyclase  
ADEPT strategy, see antibody-directed  
  enzyme prodrug therapy  
ADME, 11, 153, 248  
adozelesin, 529, 531, 570  
ADP, See adenosine 5'-diphosphate  
adrenal cortex, 689  
adrenal gland tumours, treatment of, 624  
adrenal medulla, 579, 609, 611–12  
adrenaline, 578, 609–11, 616–18,  
  see also adrenergic agonists, adrenergic  
  antagonists, and adrenergic receptors  
  as a lead compound, 204  
  as a vasoconstrictor, 170, 265, 616  
  binding site interactions, 614–16  
  biosynthesis, 611–12  
  effects on the peripheral nervous system,  
  579, 581  
  fight or flight response, 44, 579, 609  
  metabolism, 618  
  relaxation of heart muscle, 63  
  role in fat metabolism, 63  
  role in glycogen breakdown, 37–9, 60–2  
  structure and properties, 338–41  
  treatment of asthma, 618  
adrenergic agents, clinical aspects, 611  
adrenergic agonists, 116, 616–20  
adrenergic antagonists, 234–5, 620–6 see also  
  beta blockers  
adrenergic nervous system, 609

- adrenergic receptors, 50, 609–11  
 binding site, 51, 614–17  
 distribution, 610  
 evolutionary tree, 51–2  
 in the peripheral nervous system, 579  
 neurotransmission process, 612–14  
 physiological effects, 610, 618  
 presynaptic control systems, 580, 613  
 role in fat metabolism, 63  
 role in glycogen metabolism, 60, 62–3  
 role in smooth muscle contraction, 63  
 signal transduction, 58, 60–3  
 target for antidepressants, 701  
 types and subtypes, 45, 52, 115, 609–10  
 X-ray crystal structure, 53, 367, 614
- adrenoceptors, 192. *See* adrenergic receptors
- adrenocortical tumours, treatment of, 540
- adrenocorticoids, 689
- adriamycin, 524, 717
- adsorption, 469–70, 497  
 HIV, 476
- aerobic bacteria, 716
- affinity, 116
- affinity constant ( $K_i$ ), 117
- affinity screening, 197
- African bush willow, 541
- African clawed frog, 201
- AG-1254, 490–1
- $\beta$ -agalsidase, 266, 717
- Agenerase, 722
- age-related vision loss, treatment of, 268
- Aggrastat, 722
- agonists, 102–6, 113
- AIDS, *see* acquired immune deficiency syndrome
- Airomir, 722
- Akira Endo, 180
- D-alanine, 424, 445, 448, 651
- L-alanine, 17, 22, 148–9, 705  
 ACE inhibitors, 295  
 cholinergic binding site, 368  
 decapeptide, 339  
 matrix metalloproteinase active site, 561  
 racemization, 445  
 resistance to HIV protease inhibitors, 489  
 yeast alanine tRNA, 77
- L-alanine racemase, 445
- D-alanyl-D-alanine, 197, 424–5, 445, 447
- D-alanyl-D-alanine ligase, 445
- albinism, 79
- albumin, 156–7, 385, 436
- albuterol, 619, *see* salbutamol  
 formulation, 173
- Alchemy, 338
- alclometasone, 732
- alclometasone dipropionate, 693, 717
- alcohol, 2, 157, 169, 208  
 aversion therapy, 261  
 cure for antifreeze poisoning, 88
- alcohol dehydrogenases, 88–9, 160, 162–3
- alcoholism, treatment of, 89, 208, 639–40
- alcohols, binding role, 216–17
- Aldara, 722
- aldehyde dehydrogenases, 160
- aldehyde oxidase, 473
- aldehydes, binding role, 218
- aldesleukin, 566, 717
- Aldomet, 722
- aldometasone dipropionate, 692
- Aldosterone, 689–90
- alemtuzumab, 569, 717
- alfacon-1, 511
- alfentanil, 643
- alferon, 511
- algae, 716
- algorithms, 337
- Alimta, 722
- aliphatic electronic substituent constants, 390
- aliskiren, 91–2, 717, 732
- alkaline phosphatase, 572
- alkaloids, *see* atropine, camptothecin, cocaine, codeine, huperzine, hyoscine, morphine, pilocarpine, thebaine, vinca alkaloids
- alkenes, binding role, 218
- Alkeran, 722
- alkyl fluorides, 223
- alkyl halides, binding role, 222
- alkyl substituents, *see also* variation of alkyl substituents  
 binding role, 223  
 variation in drug design, 228–31
- alkylated N- morphine analogues, synthesis of, 639
- alkylating agents, 89, 126–7, 522, 526–30, 572  
 oxamniquine, 309
- alkylation  
 by alkyl halides, 222–3
- Allegra, 166, 722
- AlleGrow, 378
- allergic reactions to penicillin, 423
- allergies, treatment of, *see* anti-allergic agents
- allopurinol, 96, 717, 732
- allosteric binding sites, 36, 56, 89–90, 111
- allosteric inhibitors, 479, 535, 555
- allosteric modulators, 56, 106, 110–11
- N-allylmorphine, 648
- aloe plant, 212
- altanserin, 369
- Alvesco, 722
- Alzheimer's disease, treatment of, 96, 603, 630
- amantadine, 471, 498, 717, 732
- American mandrake, 540
- Ames test, 194
- amides  
 binding role, 219–20  
 synthesis, 322, 325–6
- amines, binding role, 218–19
- amino acid conjugates, 165
- amino acid N-acyltransferase, 165
- aminoacridines, 120, 459–60
- aminoacyl t-RNA, 452
- aminoacyl t-RNA synthetases, 464
- para*-aminobenzoic acid, 419
- $\gamma$ -aminobutyric acid, 44, 51, 700, 712
- $\gamma$ -aminobutyric acid receptors, 56, 106, 112, 206, 386
- 7-aminoccephalosporinic acid, 437–8
- aminoglutethimide, 208, 539, 717, 732
- aminoglycosides, 200, 414, 452–3, 464
- 5-aminolevulinic acid, 574, 717, 732
- 4-amino-Neu5Ac2en, 501–2
- 6-aminopenicillanic acid, 422, 428–9
- aminopenicillins, 433
- aminopeptidase enzyme, 262, 545
- para*-aminosalicylic acid, 453
- amitriptyline, 627–8
- amoebic dysentery, 716
- amoxicillin, 433, 444, 717, 732  
 clinical aspects, 435, 462  
 treatment of *Helicobacter pylori*, 659, 685–6
- Amoxil, 722
- amoxicillin, *see* amoxicillin
- AMP, *see* adenosine 5'-monophosphate
- amphetamines, 172, 616–17, 629, 700
- amphotericin, 143–5, 717, 732
- ampicillin, 263–4, 430, 432–5, 445, 717, 732
- ampicillin-resistant *H. influenza*, 462
- amprenavir, 478, 491–4, 717, 732
- amprotopine, 589
- amsacrine, 525, 717, 732
- Amsidine, 722
- $\beta$ -amyloid protein, 604–5
- anabaseine, 603–4
- Anacetrapib, 184
- anaerobic bacteria, 716
- analgesic receptors, *see* opioid receptors
- analgesics, 115, 202, 255, 261, 265, 618, *see also* opioids
- anandamide, 206, 700
- Anapen, 616
- anaphylactic reactions, treatment of, 616
- anastrozole, 539–40, 717, 732
- anchimeric assistance, 124, 584
- anchor, 315–16
- anchor and grow programs, 362–6
- anchors, 147
- androgens, 537–40
- androstenedione, 539
- Anectine, 722
- angina, treatment of, 207, 611, 622, 624–5
- angiogenesis, 515, 519–21, 561  
 inhibition, 542, 565–66
- angiogenesis inhibitors, 520–1
- angioplasty, 171
- angiostatin, 520, 566
- angiostatin II receptors, 52, 192  
 antagonists, 292
- angiotensin-converting enzyme, 91, 192, 292, 294, 296  
 inhibitors, 2, 96, 233, 292–8, *see also* captopril, cilazapril, enalaprilate, and lisinopril
- angiotensinogen, 91, 292
- angiotensins, 44, 51, 91, 292, 295, 297, 624
- anilino piperidines, 642
- annealing, 81

- Antabuse, 89, 208, 722  
 antacids, 659  
 antagonists, 102, 106–11, 113  
 antedrug, 167  
 anthracyclines, 121, 524–5  
   resistance, 523  
 anthraquinone, 563  
 anthrax, treatment of, 423, 454, 459  
*Anthriscus sylvestris*, 540  
 anti-allergic agents, 115, 204, 398  
 anti-androgens, 538  
 anti-angiogenesis agents, 564, 566  
 anti-arthritis agent, 255  
 anti-asthmatics, 256, 268, 618–20  
   administration, 170  
 antibacterial agents, 249, 413–67, 659, 685  
 antibodies, 149, 151, 267–8  
   abzymes, 572  
   anticancer therapy, 568–70, 572  
   antiviral agents, 511  
   chimeric, 267  
   fusion protein, 266  
   humanized, 268  
   hybrid, 572  
   inhibiting protein–protein interactions,  
     139–41  
   linking drugs, 571  
   monoclonal, 257  
   murine, 267  
   reduction of disulphide links, 570  
   targeting drugs, 174–5, 257  
 antibody-directed abzyme prodrug therapy  
   ADAPT, 572  
 antibody-directed enzyme prodrug therapy  
   ADEPT, 570, 572  
 antibody–drug conjugates, 174, 568–71  
 antibody–enzyme complex, 570  
 anticancer agents, 96, 242, 267, 272, 280,  
   514–74  
 anticholinergic agents, 202, 660, 662, *see also*  
   cholinergic antagonists  
 anticholinesterase poisoning, antidote, 588  
 anticholinesterases, 404, 595–608  
 anticoagulant, 280  
 anticoagulants, 141, 166, 204, 212, 280, 492  
   effect of aspirin, 171  
 anticodon, 77, 79  
 antidepressants, 204, 594, 700–1, *see also*  
   monoamine oxidase inhibitors, tricyclic  
   antidepressants, selective noradrenaline  
   reuptake inhibitors, selective serotonin  
   reuptake inhibitors  
   adrenergic antagonists, 621  
   dopamine antagonists, 115, 189  
   drug–drug interactions, 172  
   dual action agents, 701  
   reuptake inhibitors, 135–6  
   serotonin agonist, 205  
   serotonin antagonists, 287, 701–4  
 antidiabetic agents, 204, 253  
 antidiarrhoeal agents, *see* diarrhoea  
   treatments  
 anti-diuretic hormone, 169  
 antidotes  
   anticholinesterase poisoning, 588  
   atropine poisoning, 599  
   curare poisoning, 599  
   to lewisite, 96  
   to morphine overdose, 115  
   to organophosphates, 602–3  
 anti-emetics, 115, 192  
 antiepileptics, *see* epilepsy treatments  
 anti-estrogens, 538–9  
 antifreeze poisoning, 88  
 antifungal agents, 191, 233, 249, 254, 258,  
   275, 464  
 antigenic drift, 498  
 antigenic variation, 498  
 antigens, 149, 151, 175, 257, 470, 497, 568  
 anti-growth factors, 517  
 antihistamines, 166, 193, 205, 208  
 anti-HIV drugs, *see* HIV  
 antihypertensive agents, 203, 620, 627,  
   700, *see also* angiotension-converting  
   enzyme inhibitors, beta-blockers,  
   adrenergic antagonists, clonidine,  
   cromkalim, losartan, and renin  
   inhibitors  
 anti-impotence drugs, 204  
 anti-inflammatory agents, 96, 222, 279–80,  
   565, 689–99  
 antimalarial agents, 204, 260, 299–304, 393  
   doxycycline, 454  
 antimetabolites, 416, 531–6  
 antimicrobial agents, *see* antibacterial agents,  
   antifungal agents, and antiprotozoal  
   agents  
 antimigraine agents, 115  
 anti-obesity agents,  
   adrenergic agonists, 116, 287, 617  
   lipase inhibitors, 89–90, 200  
   melanin concentrating hormone receptor  
   antagonists, 194  
   reuptake inhibitors, 135, 629  
 antioncogenes, 515  
 antiparasitic drugs, 465  
 antiprotozoal agents, 2–3, 414, 461–2,  
   *see also* antimalarial agents and  
   oxamniquine  
 antipsychotics, 114, 116, 191, 235, 260–1  
 antirheumatic agent, 251  
 antisense therapy, 131–2, 175, 271, 475,  
   493–4, 529  
 antiseptic, 413  
 antismoking drugs, 204, 594, 629  
 antithrombotic agents, 250  
 antituberculosis agents, *see* tuberculosis  
   treatments  
 antitumour agents, *see* anticancer agents  
 antiulcer agents, 115, 457, 462, 588–9,  
   659–88, *see also* ulcers, treatment of  
 antiviral agents, 234, 275, 468–511  
 antrum, 659  
 ants, 603  
 anxiety  
   treatment of, 200, 624  
 aorta, 156  
 6-APA, *see* 6-aminopenicillanic acid  
 Apaf-1 protein, 518  
 apomorphine, 340  
 apoptosis, 142, 515, 517–19  
 apoptosome, 518  
 appetite, control of, 200  
 appetite stimulants, 206  
 apricots, 3  
 Apsin, 722  
 aptamers, 143, 271  
 aquaporins, 168  
 arabinosyl transferase enzymes, 461  
 ara-C, 534  
 2-arachidonyl glycerol, 206  
 arachidonylethanolamine, 206  
 ara-CTP, 535–6  
 ara-G, 534  
 area under the plasma drug concentration  
   curve (AUC), 173  
 arecoline, 586–7  
 Arf protein, 67  
 arginine, 17, 21–2, 670–1, 705  
   ACE binding site, 293–4, 296  
   binding of statins, 183–4  
   carboxypeptidase binding site, 293  
   neuraminidase binding site,  
     499–501, 503  
   role in depression, 700  
   synthesis of nitric oxide, 38  
 Aricept, 722  
 Arimidex, 722  
 armodafinil, 282–3, 717  
 aromatase, 538–9  
   inhibitors, 538–9  
 aromatic L-aminoacid decarboxylase, 612  
 aromatic rings, binding role, 217–18  
 aromatic substituents, variation in drug  
   design, 229–31, *see also* variation of  
   aromatic substituents  
 arrhythmia, treatment of, 622, 624  
 arsenic, 2  
 arsenic trioxide, 566, 717, 732  
 arsenite, 96  
*Artabotrys uncinatus*, 304  
 arteether, 300, 303  
 arteflene, 304  
 artether, 300, 303  
*Artemisia annua*, 299–300  
 artemisinin, 199–200, 202, 299–303  
 Artemisinin Combination Therapy, 303  
 arthritis, 27  
   treatment, 93, 212, 266, 268, 279, 405  
 arthropods, 468  
 artificial viruses, 83, 175  
 aryl halides  
   binding agents, 223  
   binding role, 222  
 aryloxypropanolamines, 622–3  
 Arzerra, 722  
 asbestos, 515  
 Asian flu, 496  
 Asmabec Clickhaler, 722  
 Asmanex, 722  
 Asmasal Clickhaler, 722  
 asparaginase, 267, 567

- asparagine, 17, 705  
 cholinergic binding site, 368, 584  
 glycoproteins, 25  
 in leukaemia cells, 567  
 in protease inhibitors, 485–6, 490  
 mutation in reverse transcriptase, 479  
 rigidification, 239
- aspartate (aspartic acid), 17, 21–2, 705  
 acetylcholinesterase active site, 597  
 adrenergic receptor binding site, 614–15  
 binding of protease inhibitors, 484–9,  
 491–2  
 binding to estrogen antagonists, 110  
 catalytic triad, 34, 90  
 cholinergic binding site, 583  
 HIV-protease binding site, 482–4, 489  
 HMG-CoA reductase active site, 179–80  
 in fibrinogen, 141  
 kinase active site, 553–5, 558  
 lipase active site, 90  
 mechanism of renin, 91  
 mimic, 190  
 neuraminidase active site, 499–501,  
 503, 505  
 proton acceptor, 33  
 proton donor, 33  
 receptor binding sites, 367–8  
 substrates for caspases, 190  
 thymidylate kinase active site, 407–10
- aspartic acid, *see* aspartate
- aspartyl proteases, 481
- aspergillosis, 716
- Aspergillus alliaceus*, 200
- Aspergillus sclerotiorum*, 310
- Aspergillus terreus*, 181
- asperlicin, 200, 237
- aspirin, 3, 212, 278, 522, 632  
 as a prodrug, 261  
 as an acylating agent, 222  
 drug–drug interactions, 171  
 interaction with cyclooxygenases, 96,  
 222, 659  
 role in causing ulcers, 659  
 synthesis of, 285–6
- synthesis of salbutamol, 619
- Association of British Pharmaceutical  
 Industry, 284
- astemizole, 204, 481
- asthma, treatment of, 192–3, 212, 268, 611,  
 661, 694–6, *see also* antiasthmatics and  
 salbutamol
- Astra, 287, 684
- AstraZeneca, 546, 550
- asymmetric compounds, 104
- asymmetric synthesis, 104
- atazanavir, 478, 492, 494, 717, 732
- atenolol, 624–6, 717, 732
- athletes foot, treatment of, 143
- atomoxetine, 629, 717, 732
- atorvastatin, 154, 178, 181–4, 717, 732
- ATP, *see* adenosine 5'-triphosphate
- ATPase, 680
- ATP-binding cassette (ABC)  
 transporters, 523
- atracurium, 592–3, 717, 732
- $\alpha$ -atrial natriuretic peptide, 68
- Atripla, 722
- Atropa belladonna*, 588
- atropine, 202, 588–9
- atropine methonitrate, 589
- atropine poisoning, antidote, 599
- atropine sulphate, 718
- Atrovent, 722
- attention deficit hyperactivity disorder,  
 treatment of, 629
- AUC, *see* area under the plasma drug  
 concentration curve
- Augmentin, 444, 722
- Aureocort, 722
- aureomycin, 454
- auristatin PE, 566–67
- auristatins, 569
- AutoDock, 361, 366
- autoimmune disease, 586  
 treatment of, 190
- autonomic motor nervous system, 579
- autoreceptors, 12, 580, 621, 701
- Avalox, 722
- Avamys, 722
- Avastin, 722
- Avelox, 722
- Avloclor, 722
- avridine, 511
- Axid, 722
- axon, 711
- Azactam, 722
- Azadirachta indica*, 687
- azathioprine, 260–1, 717, 732
- AZD3409, 546
- azidothymidine, 478, *see* zidovudine
- azithromycin, 456–7, 717, 732
- azlocillin, 435
- AZT, *see* zidovudine
- Aztec, 202
- aztreonam, 444, 717, 732

## B

- bacampicillin, 434
- Bacillus polymyxa*, 450
- Bacillus subtilis*, 445
- bacitracin, 414, 445–6, 451–2, 717, 732
- bacteria, 716
- bacterial carboxypeptidase, 570
- bacterial cell, 415
- bacterial pneumonia, treatment of, 442
- bacterial RNA polymerase, inhibitors of, 461
- bactericidal, definition, 419
- bacteriophages, 82, 463
- bacteriorhodopsin, 367, 369
- bacteriostatic, definition, 418
- Bacteroides fragilis*, 442, 715  
 treatment of, 457, 462
- Bactroban, 722
- Bad protein, 518
- bar coding, 331
- barbiturates, 1, 156, 157, 386, 594
- Barlos resin, 315–16
- base pairing, 72–4, 76, 224–5  
 abnormal for guanine, 124
- basil, 3
- Bax protein, 518, 563
- BAY12-9655, 562–3
- Baycol, 722
- bazinaprine, 205
- Bcl-2 protein, 272, 518–19, 529
- BCI-x protein, 142–3, 518–19
- BCNU, 722
- Bcr-Abl kinase inhibitors, 559
- BCX-1812, 506
- beclomethasone dipropionate, 692, 694–5,  
 717, 733
- beclomethasone dipropionate, 692, *see*  
 beclomethasone dipropionate
- Becodisks, 722
- Beconase, 722
- bee sting, 616
- Beechams Pharmaceuticals, 422, 428,  
 433, 444
- belimumab, 268, 717
- belladonna, 588
- Benadryl, 661, 722
- bendamustine, 527–8, 530, 717, 733
- benextramine, 606
- benign prostatic hyperplasia, treatment  
 of, 620
- benign tumours, 514, 521
- Benlysta, 722
- Benuryl, 722
- Benylin, 617
- benzalkonium chloride, 719
- benzatropine, 589–90, 717, 733
- benzhexol, *see* trihexyphenidyl
- benzodiazepines, 106, 206  
 solid phase synthesis, 317
- benzoic acid, ionization, 388
- benzomorphans, 641–2
- benztropine, *see* benzatropine
- benzylpenicillin (penicillin G), 422–3,  
 426–7, 429–30, 463, 717, 733
- L-benzylsuccinic acid, 206, 292–4
- Bergman cyclization, 128
- besifloxacin, 459, 717, 733
- Besivance, 722
- beta blockers, *see*  $\beta$ -blockers
- beta lactams, *see*  $\beta$ -lactams
- Betacap, 722
- Betaloc, 722
- betamethasone, 690–2, 694, 717, 733
- betamethasone dipropionate, 692, 694,  
 717, 733
- betamethasone sodium phosphate, 696,  
 717, 733
- betamethasone valerate, 692, 694,  
 717, 733
- betaxolol, 624–6, 717, 733
- Betesil, 722
- bethanechol, 586, 717, 733
- Betim, 722
- Betnelan, 722
- Betnesol, 722
- Betnesol-N, 722

- Betnovate, 722  
 Betnovate-C, 722  
 Betnovate-N, 722  
 Betoptic, 722  
 Bettamousse, 722  
 bevacizumab, 143, 268, 285, 569, 717  
 Bextra, 722  
 Bexxar, 722  
 BIAcore, 197  
 BiCNU, 722  
 bicyclams, 495  
 bile duct, 167  
 bilharzia, 305  
 biliary tract infections, treatment of, 453  
 Bill and Melinda Gates Foundation, 189  
 binding efficiency, 211  
 binding groups, 5, 46, 102–5  
 binding regions, 5, 32, 46  
 binding site, 4–5, 45, *see also* allosteric binding sites  
   adrenergic receptors, 614–15  
   catecholamine receptors, 368  
   cholinergic receptor, 368  
   construction of, 368  
   estrogen receptor, 109–10  
   G-protein coupled receptors, 368  
   model, 369  
   muscarinic receptor, 583  
 bioassays, 195–9  
 bioavailability, 173, 278  
 Biocef, 722  
 bio-equivalence studies, 278  
 bio-isosteres, 234, 236, 251, 268–9, 397, 489, 542  
   for alpha, beta-unsaturated esters, 259–60  
   for carboxylic acid, 250–1  
   for methyl group, 550, 586  
   for phenols, 251  
   for phosphate, 473  
   for thiourea, 672  
   serotonin antagonists, 703  
 biomarker, 280  
 Biota pharmaceuticals, 502  
 bioterrorism, 468, 511  
 birocodar, 523  
 bis(7)-tacrine, 605  
 bismuth, 462  
 bismuth chelate, 686  
 bismuth subcitrate, 686  
 Black, James, 622  
 bladder cancer, treatment of, 530, 534  
 Bld protein, 518  
 bleomycins, 121–2, 128, 525  
 blinatumomab, 568  
 $\beta$ -blockers, 115, 279, 621–6, *see also* adrenergic antagonists  
   short acting, 625–6  
 blood clotting, inhibition, 140  
 blood–brain barrier, 156–7, 195  
 bloodshot eyes, treatment of, 618  
 blue green algae, 541, 716  
 BMS-184476, 137–8  
 BMS-188797, 137–8  
 BMS-247550, 542  
 BMS-275291, 562  
 BMS-378806, 495  
 boceprevir, 508–9, 717, 733  
 boils, treatment of, 413, 462  
 $\pi$ -bond cooperativity, 225  
 bone infections, treatment of, 457, 459  
 bortezomib, 96, 563, 717, 733  
 bosutinib, 555  
 botulism, 202  
 bradykinin, 44  
   receptor, 51  
 brain abscesses, treatment of, 462  
 brain natriuretic peptide, 68  
 brain tumours, treatment of, 530  
 Brazilian viper, 202  
 breast cancer, 514–15, 517, 522  
   treatment with alkylating agents, 530  
   treatment with antibodies, 569  
   treatment with antimetabolites, 533, 534  
   treatment with aromatase inhibitors, 538–9  
   treatment with drugs acting on tubulin, 543  
   treatment with hormone-based therapies, 540  
   treatment with intercalating agents, 525  
   treatment with kinase inhibitors, 559  
   treatment with pancratistatin, 566  
   treatment with raloxifene, 110  
   treatment with tamoxifen, 115  
 breast milk, 167  
 bremazocine, 641  
 brentuximab vedotin, 569, 717  
 bretylium, 627–8  
 Brevibloc, 722  
 Bridion, 722  
 British Approved Name, 12  
 British National Formulary for Children, 280  
 broad-spectrum antibiotics, 433  
 broad-spectrum antiviral agents, 510–11  
 broad-spectrum penicillins, 433–6  
   clinical aspects, 435  
 broccoli, 3, 522  
 Broflex, 722  
 bromodomain, 567  
 bronchitis, treatment of, 435, 459  
 bronchodilator, 589, 617  
 Brookhaven National Laboratory Protein Data Bank, 20, 353, 355  
 Brucellosis, treatment of, 453, 462  
 Brussels sprouts, 166  
 bryostatins, 201, 566  
 bubonic plague, 414  
 budding, 470  
 Budelin Novolizer, 722  
 budesonide, 692, 695–6  
 bungarotoxin, 201, 594–5  
 bupivacaine, 282, 717, 733  
 buprenorphine, 645, 647, 649, 717, 733  
 bupropion, 204, 594, 629, 639, 717, 720, 733  
 burimamide, 206, 665, 667–9  
 Burkitt's lymphoma, 514  
   treatment of, 472, 522  
 burns, treatment of, 417  
 Busilvex, 722  
 busulfan, 124–6, 530, 717, 733  
 busulphan, *see* busulfan  
 butorphanol, 649  
 N-butyldeoxynojirimycin, 495  
 butyrylcholinesterase, 595–6  
 bystander effect, 573
- C**
- C55 carrier lipid, 445  
 CaaX peptide, 545  
 cabbage, 3, 522  
 CAChe, 338  
 Caco-2 cell monolayer absorption model, 195  
 cadherins, 521  
 CAESA, 376  
 caffeine, 2, 278  
 calabar bean, 598  
 calcitonin, 266  
 calcium carbonate, 659  
 calcium-dependent protein kinases, 65  
 calcium ion channel blocker, 523  
 calcium ion channels, 59, 65, 192  
 calcium ions, 65, 67  
 calcium-sensing receptor, 106  
 Calcort, 722  
 calicheamicin, 128–9, 529, 570–1  
 calmodulin, 65–6, 142  
 Cambridge Structural Database, 339, 353  
 Camcolit, 722  
 cAMP, *see* cyclic AMP  
 Campto, 722  
 Camptosar, 722  
*Camptotheca acuminata*, 122, 526  
 camptothecin, 122–3, 526  
 canaliculus, 679–80  
 cancer, 514–23  
 cancer chemotherapy, *see* anticancer agents  
 cancer stem cells, 523  
 candidiasis, 716  
 candoxatril, 260, 265  
 candoxatrilat, 260  
 Canesten, 722  
 cannabinoid antagonists, 116  
 cannabinoid receptors, 206  
 cannabis, 1–2, 170  
 capecitabine, 533–4, 559, 717, 733  
 Capoten, 722  
 Caprelsa, 722  
 caproctamine, 606, 607  
 capsid, 135, 469  
 capsid-binding agents, 507–8  
 capsules, 12, 169, 173, 277–8, 494  
 captopril, 96, 320, 717, 733  
   active conformation, 354  
   as a lead compound, 203–4  
   design of, 293–4  
   rigidification of, 239  
   side effects, 294  
   synthesis of, 297  
 Carace, 722  
 carbachol, 586



- carbapenems, 442–3  
 carbenicillin, 433, 435  
 carbenoxolone, 687, 717, 733  
 carbidopa, 265, 717, 733  
 carbohydrates, 25, 148–51  
 in antibodies, 569–70  
*see also* aminoglycosides, anthracyclines,  
 N-butyldeoxynojirimycin,  
 cyclodextrins, deoxyribose, glucose,  
 glycoconjugates, glycoproteins,  
 macrolides, peptidoglycan,  
 podophyllotoxins, ribose, sialic acid,  
 vancomycin  
 carbolic acid, 413  
 carbon buckyballs, 83  
 carbonic anhydrase, 40, 205, 333, 679, 680  
 carboplatin, 190, 529–30, 718, 733  
 carboxamides, 502–5  
 carboxylate ion, binding role, 221  
 carboxylation, 25  
 carboxylesterases, 526–7, 572  
 carboxylic acids, binding role, 221  
 carboxypenicillins, 433, 435  
 carboxypeptidases, 292–3, 570–3  
   inhibitor, 293  
 carbuncles, treatment of, 413  
 carcinogenesis, 514  
 cardiac arrest, treatment of, 616  
 cardiac failure, treatment of, 620  
 cardiac stimulant, 617  
 cardiogenic shock, treatment of, 617  
 cardiogenic agents, 387  
 cardiovascular drugs, 586, 621, *see also*  
   antihypertensive agents  
 Cardura, 722  
 Carelux, 722  
 carfecillin, 433, 435  
 carmustine, 124, 126, 530, 718, 733  
 carrier lipids, *see* C55 carrier lipid  
 carrier proteins, *see* transport proteins  
 carvedilol, 620–1  
 caspases, 97, 190, 518, 564  
   inhibitors, 190  
 catalase-peroxidase enzyme, 461  
 catalytic triad, 34, 90, 597, 598  
 Catapres, 723  
 catch and release, 324–5  
 catechols, 340, 611, *see also* catecholamines  
 catecholamine receptors, 368, *see also*  
   adrenergic and dopamine receptors  
 catecholamines, 611–12, *see also* adrenaline,  
   adrenergic agonists, dopamine and  
   noradrenaline  
 catechol-O-methyltransferase, 162, 254, 612,  
   617–18  
*Catharanthus roseus*, 540  
 cathepsin D, 482  
 cation- $\pi$  interaction, 9, 221  
 cauliflower, 3, 522  
 CB-3717, 407–8  
 CC-1065, 529, 531  
 CCK, *see* cholecystokinin  
 CCNU, 723  
 CCR5 antagonist, 495  
 CCR5 receptor, 477, 495  
 CD4 protein, 476–7, 495  
 CD20 antigen, 570  
 CD20 receptor, 569  
 CD33 antigen, 571  
 CD52 antigen, 569  
 CD117 receptor, 559  
 CDKs, *see* cyclin-dependent kinases  
 cefalexin, 253, 438–9, 442, 718, 733  
 cefalothin, 718, 733, *see also* cephalotin  
 cefalotin, *see* cefalothin  
 cefazolin, 438, 440, 442  
 cefepime, 440–1  
 cefotaxime, 440–1, 718, 733  
 cefoxitin, 252, 440, 442, 718, 733  
 cefpirome, 440–2, 718, 733  
 Cefrom, 723  
 ceftaroline, 441  
 ceftaroline fosamil, 441–2, 718, 733  
 ceftazidime, 440–2, 718, 733  
 ceftizoxime, 440–1  
 cefotibiprole, 718, 733  
 ceftriaxone, 440–2, 718, 733  
 cefuroxime, 440, 442, 718, 733  
 Celebrix, 723  
 celecoxib, 93, 95, 718, 733  
 cell adhesion molecules, 521  
 cell cycle regulation, 516–17  
 cell death, *see* apoptosis and caspases  
 cell entry inhibitors, 494–5  
 cell membrane, 3  
 cell wall structure, 423–4  
 cellulose, 148  
 Celsenti, 723  
 central dogma, 77  
 central nervous system, 42–3  
 central nervous system infections, treatment  
   of, 462  
 centroid, 227, 352  
   scaffold, 318  
 centromere, 519  
 cephalixin, *see* cefalexin  
 cephaloridine, 253, 438–9, 441  
 cephalosporin C, 414, 436–7, 442  
 cephalosporin prodrug, 572  
 cephalosporinases, 428, *see also*  
    $\beta$ -lactamases  
 cephalosporins, 200, 436–41, 464–5  
*Cephalosporium acremonium*, 436  
 cephalostatin, 143, 201, 566–7  
 cephalothin, 438–9, 442, *see also* cefalothin  
 cephamycins, 439–41  
 Ceporex, 723  
 Cerep, 703  
 Cerezyme, 723  
 cerivastatin, 181–2, 279–80, 718, 733  
 Certican, 723  
 cerubidine, 524  
 cervical cancer, 514  
   treatment of, 530, 534  
 cetuximab, 569, 718  
 cGMP, *see* cyclic GMP  
 CGP-52411, 252–3  
 CGP-53353, 253  
 CGP-53716, 553  
 CGS-27023A, 562–3  
 Chain, *see* Florey and Chain  
 chain contraction, 231, 233, 242, 589  
 chain cutters, 128, 529  
 chain extension, 231, 233, 622, 667  
   ACE inhibitors, 296  
   oxamniquine, 306  
 chain termination, 535  
 chain terminators, 120, 129–30, 139, 472  
 Chantix, 723  
 chaperones, 28  
 cheese reaction, 630  
 Chem3D, 338  
 ChemDraw, 338  
 chemical development, 285–6  
 chemokine receptors, 477, 495  
 chemotherapeutic index, 414  
 chemotherapy, 413, 514  
 ChemWindow, 338  
 cherries, 3  
 chickenpox, 468  
   treatment of, 472, 475  
 chimeric antibodies, *see* antibodies  
 chimeric drug, 244  
 Chinese Hamster Ovarian cells, 195  
 chiral compounds, 104  
 chiral switching, 136, 282, 619, 684  
 Chirocaine, 723  
 Chlamydia, treatment of, 454  
 chlorambucil, 527–8, 530, 718, 733  
 chloramphenicol, 200, 262, 280, 414, 452,  
   454–6, 718, 733  
 chloramphenicol acetyltransferase, 454  
 chloramphenicol palmitate, 262  
 chloramphenicol succinate, 262  
 chloramphenicol-resistant meningococci,  
   462  
 chlordiazepoxide, 718, 734, *see also* Librium  
 chlorhexidine, 719  
 chloride ion channels, 712, *see also*  
    $\gamma$ -aminobutyric acid receptors and  
   glycine receptors  
 chlorins, 264, 573  
 chlormethine, 124–5, 526–8, 530  
 chloroform, 386  
 Chloromycetin, 723  
 chlorophyll, 573  
 chloroquine, 299, 718, 734  
 chlorothiazide, 205  
 chlorpromazine, 205, 208, 718, 734  
 chlorpropamide, 253  
 chlorpyrifos, 601  
 chlortetracycline, 414, 454–5, 718, 721, 734  
 CHO cells, *see* Chinese hamster ovarian  
   cells  
 cholecystokinin, 200, 237  
 cholera, 413  
 cholesterol, 178, 212, 689  
 cholesterol conjugates, 163  
 cholesterol-lowering agents, 96, 133, 169,  
   238, 279, *see also* statins  
 cholesteryl ester transfer protein, 184  
 cholestyramine, *see* colestyramine

- choline, 580–1, 597  
 choline acetyltransferase, 580–1  
 cholinergic agonists, 582–7  
 cholinergic antagonists, *see* muscarinic antagonists and nicotinic antagonists  
 cholinergic nervous system, 580–1, 613  
 cholinergic receptors, 45, 579, 582, 660, *see also* muscarinic and nicotinic receptors  
*Chondrodendron tomentosum*, 591  
 chromatin, 76, 519, 564  
*Chromobacterium violaceum*, 444  
 chromogranin A, 612  
 chromosomes, algorithms, 350–1  
 chronic myeloid leukaemia, treatment of, 559  
 Churchill, Winston, 417  
 chymotrypsin, 20, 34, 563  
 Cicatrin, 723  
 ciclesonide, 692, 695–6, 718, 734  
 ciclosporin, 200–1, 208, 523, 718, 734  
   absorption, 154  
   administration, 270  
   metabolism, 166  
 cidofovir, 473–5, 718, 734  
 Cidomycin, 723  
 cigarette, 170  
 cigarette smoke, 166  
 cilastatin, 443, 718, 734  
 cilazapril, 202, 204, 239, 718, 734  
 cilazaprilat, 233  
 cimetidine, 166, 659–61, 670–3, 679, 718, 734  
 cinacalcet, 106–7  
 cinchona bark, 202  
 Cipralext, 723  
 Cipramil, 723  
 Cipro, 723  
 Ciprobay, 723  
 ciprofloxacin, 414, 458–9, 718, 734  
 Ciproxan, 723  
 Ciproxin, 723  
 cisapride, 193  
 cisplatin, 125, 127, 522, 529–30, 534, 566, 568  
 citalopram, 136, 718, 734  
 citrulline, 38  
 CJS-149, 570  
 CKIs, *see* cyclin-dependent kinase inhibitors  
 c-Kit protein, inhibition of 552–5, 559  
 Claforan, 723  
 clarithromycin, 455–7, 685–6, 718, 734  
 Clarosip, 723  
 clavulanic acid, 92–3, 422, 435–6, 444–5, 718, 734  
 Clenil Modulite, 723  
 click chemistry *in situ*, 210–11  
 clindamycin, 263, 455–7, 718, 734  
 clindamycin phosphate, 263, 455  
 clinical trials, 277–80  
 clioquinol, 717, 719  
 clique searching, 359  
 clobetasol, 692, 734  
 clobetasol propionate, 694–5, 718, 734  
 clobetasone butyrate, 694–5, 718, 734  
 Clog *P*, 248, 387  
 clomitrazone, 719  
 clonidine, 169, 208, 617–18, 718, 734  
 clorgiline, 95–6  
*Clostridium botulinum*, 202  
*Clostridium difficile* infections, treatment of, 451, 461–2  
 clotrimazole, 717  
 cloxacillin, 432  
 clozapine, 114, 116, 718, 734  
 Clozaril, 723  
 club moss, 604  
 CML, treatment of, 559  
 CMN-131, 682, 683  
 CMV, *see* cytomegalovirus  
 CMV retinitis, treatment of, 475  
 CNS infections, treatment of, 453  
 coactivator proteins, 56, 109–10, 140, 567  
 coagulation factors, 80–1  
 coal dust, 515  
 co-amoxiclav, 718  
 cobras, 201  
 coca bush, 202  
 coca leaves, 629  
 cocaine, 2, 642, 700  
   ability to cross placental barrier, 157  
   administration of, 169–70  
   lead compound for local anaesthetics, 237  
   mode of action, 135, 629  
   overlay with procaine, 351–2  
   source, 199, 202  
 co-careldopa, 265, 718  
 cocoa, 2  
 codeine, 160, 164, 633–4, 637–8, 653  
 coenzyme A, 179–80, 182–3, *see also* acetyl coenzyme A  
 coenzyme F, 419  
 coenzymes, 35–6  
 cofactor, competition with inhibitors, 88  
 cofactors, 20, 35  
 coffee, 2  
 co-fluampicil, 432, 723  
 Cogentin, 723  
 Cognex, 723  
 colchicine, 136–7, 244, 404–5, 540–1  
 cold sores, 468  
   treatment of, 472, 475  
 cold virus, 507  
 colestyramine, 169, 718  
 collagenases, 561  
 colon cancer, 522, 544  
   treatment of, 533  
 colony stimulating factors, 266  
 Colorado tick fever, 468  
 colorectal cancer, treatment of, 527, 530, 533–4, 569  
 CoMASA, 404  
 combination therapies, 193  
 combinatorial libraries, 329  
 combinatorial synthesis, 313–34  
   planning, 379  
 combretastatins, 541–2  
*Combretum caffrum*, 541  
 CoMFA, 342, 401, 403–5  
 comfrey, 687  
 CoMMA, 404  
 common cold, 468  
 compactin, 180–1, 718, 734  
 competitive inhibition, 87  
 competitive inhibitors, 88  
 compound libraries, 313, 318, 329  
   planning, 379  
 computer-aided design of lead compounds, 207  
 CoMSIA, 404  
 Condyline, 723  
 conformational analysis, 346–51, 702  
 conformational blockers, 241, 663  
 conformational design of imatinib, 552, 553  
 oxamniquine, 307–8  
 conformational explosion, 361  
 conformational space, 318  
 conjugation, 463  
 conjugation reactions, 158, 160  
 Conn's syndrome, 690  
 Connolly surface, 358  
 conotoxin, 202  
 constructs, 362  
 contraception, 115  
 contraceptives, 106, 200, 252  
   drug–drug interactions, 167, 462  
 Contrave, 723  
 convergent evolution, 52  
 Copegus, 723  
 Co-phenotrope, 723  
 Cordilox, 723  
 Corgard, 723  
 Corlan, 723  
 coronary heart disease, 178  
 correlation coefficient, 384  
 corticosterone, 689–90  
 corticotrophin-releasing factor, 700  
 cortienic acid, 697  
 cortisol, 106, 689, 691–2, 697  
 cortisone, 689–90, 693  
 cortisone acetate, 692–3  
 cortivazol, 106, 378  
 Corvitol, 723  
 Cosmegen Lyovac, 723  
 co-transmitters, 581, 612–13  
 co-trimoxazole, 420, 718  
 coughs, treatment of, 638  
 cowpox, 470  
 Cozaar, 723  
 Craig plot, 392–4  
 Crestor, 723  
 crisantaspase, 567, 718  
 Crixivan, 723  
 crizotinib, 226, 242, 556–7, 560, 718, 734  
 cromakalim, 256, 276, 342–3  
 cross-linking, 124–8, 526, 529  
 cross-validated correlation coefficient, 403  
 cross-validation, 402  
 cryptophycins, 541  
 CrystalLEAD, 210  
 Crystapen, 723  
 c-Src tyrosine kinase, 554  
 Cubicin, 723

- curacin A, 201  
 curare, 2, 591  
 curare poisoning antidote, 599  
 Cushing's syndrome, 689  
 Cutivate, 723  
 CXCR4 receptor, 477  
 cyclases, 38  
 cyclic AMP, 59–63, 595, 610  
 cyclic GMP, 38, 59, 67–8  
 cyclic lipopeptides, 451  
 cyclic peptide antibiotics, 414  
 cyclic peptides, 145  
 cyclin-dependent kinases, 19–20, 516–17, 555  
   inhibitors, 517, 555–6  
 cyclins, 516–17, 556  
 cyclodextrins, 83, 150–1  
 cycloguanil pamoate, 260–1  
 cyclohexane, 347  
 cyclooxygenase-2, 280  
 cyclooxygenases, 93, 222, 659  
   inhibitors, 95–6  
 cyclopentenyl cytosine, 510  
 cyclopentolate, 589–90, 718, 734  
 cyclophosphamide, 124, 261, 528, 530, 718, 734  
 cyclopropanecarboxylic acid esters  
   as potential prodrugs, 259–60  
 cyclopropyl group, 235  
 D-cycloserine, 445–6, 451  
 cyclosporin, *see* ciclosporin  
 Cymbalta, 723  
 Cymevene, 723  
 Cyprostat, 723  
 cyproterone acetate, 538, 540, 718, 734  
 cysteine, 17, 94, 705  
   biosynthetic building block for  $\beta$ -lactams, 422, 436–7  
   caspase active site, 190, 518  
   disulphide bonds, 21–3  
   farnesyl transferase inhibitors, 545  
   farnesylation, 545  
   glutathione conjugates, 166  
   glycolysis enzymes, 466  
   intracellular receptors, 56  
   mercury poisoning, 96  
   nicotinic receptor, 591  
   nucleophile, 34, 89  
   PEGylation of antibodies, 268  
   proton pump, 680–2  
   reaction with acrolein, 529  
   urease, 687  
 Cysticide, 723  
 Cytadren, 723  
 cytarabine, 534–6  
 cytidine triphosphate, 510  
 cytidine triphosphate synthetase, 510  
 cytochrome c, 518  
 cytochrome P450 activity, 166  
 cytochrome P450 enzymes, 126, 158–61, 163–4, 166–7, *see also* S-mephenytoin  
   hydroxylase and nifedipine hydroxylase  
   irreversible inhibition, 94  
 cytokine receptor, 559  
 cytokines, 54, 565, 700  
 cytomegalovirus (CMV) infections,  
   treatment of, 475  
 cytoplasm, 3  
 cytosine, 71–2  
   alkylation of, 126  
   nucleophilic groups, 124  
 cytosine arabinoside, 536
- D**
- D-1927, 251  
 D-2163, 562  
 dacarbazine, 126–7, 530, 718, 734  
 daclizumab, 140, 718  
 dactinomycin, 121, 524–5, 718, 734  
   resistance, 523  
 daffodils, 603  
 Daktacort, 723  
 Dalacin C, 723  
 dalfopristin, 456–7, 718, 734  
 dantron, 202  
 dapson, 462  
 daptomycin, 143, 451–2, 718  
 darunavir, 478, 491–2, 494, 718, 734  
 dasatinib, 285, 554–5, 559, 718, 734  
 database handling, 379, 380  
 database mining, 209, 366  
 dATP, *see* deoxyadenosine triphosphate  
*Datura stramonium*, 588  
 daunomycin, 524  
 daunorubicin, 524–5, 718, 734  
 DaunoXome, 723  
 dCTP, *see* deoxycytosine triphosphate  
 DDT, 299  
*de novo* drug design, 242, 370–8, 407–10, 486–7, 489  
 10-deacetylbaicocatin III, 289  
 deacetylcortivazol, 106  
 deadly nightshade, 588  
 dealkylation, 229  
 death activator proteins, 518  
 death-inducing protein, 566  
 3-deazaneplanocin A, 510  
 decamethonium, 353, 404, 592, 595  
 deflazacort, 692–3, 718, 734  
 Degarelix acetate, 565–6, 718, 734  
 degree of inhibition, 98  
 dehydropeptidase, 443  
   inhibitor, 443  
 delavirdine, 478–81, 718, 734  
 demeclocycline, 454–5, 718, 734  
 dementia, 595  
 Demerol, 723  
 demethylation, 220, 639  
   of methyl ethers, 223  
*N*-demethylation, 223, 260  
 dendrites, 711  
 dengue fever, treatment of, 470  
 Denosumab, 268, 718  
 deoxoartemisinin, 301  
 deoxodeoxyartemisinin, 301  
 2-deoxy-2,3-dehydro-*N*-acetylneuraminic  
   acid, 501, 503–4  
 deoxyadenosine, 71  
 deoxyadenosine triphosphate, 535  
   allosteric inhibitor, 535  
 deoxyartemisinin, 301  
 21-deoxybetamethasone 17-propionate,  
   692, 695  
 deoxycytidine, 71, 479, 535  
 deoxycytidine monophosphate, 473–4  
 deoxycytosine triphosphate, 535  
 deoxyguanosine, 71, 130  
 deoxyguanosine triphosphate, 472  
 deoxypodophyllotoxin, 540  
 deoxyribose, 71, 76  
 deoxythymidine, 71, 473, 478  
 deoxythymidine monophosphate, 531, *see*  
   also deoxythymidylate monophosphate  
 deoxythymidine triphosphate, 535  
 deoxythymidylate monophosphate, 407,  
   531–3, *see also* deoxythymidine  
   monophosphate  
 deoxyuridine monophosphate, 531, *see also*  
   deoxyuridylate monophosphate  
 deoxyuridylate monophosphate, 407, 531–2,  
   *see also* deoxyuridine monophosphate  
 deoxyuridylic acid monophosphate,  
   fluorinated analogue, 532  
 dependence, 114  
 depolarization, 712–13  
 Depo-Medrone, 723  
 Deprenyl, 723  
 depression, 621, 700  
   treatment of, 167, 629  
 depsipeptide, 564, 718  
 Derbac-M, 723  
 Dermovate, 723  
 Dermovate-NN, 723  
 desciclovir, 473, 475  
 desensitization, 112, 114, 621  
 desipramine, 164, 189–90, 627–8  
 Deteclo, 454, 723  
 deuterium  
   as a metabolic blocker, 253, 492  
 devazepide, 237  
 dexamethasone, 692  
 dexamethasone, 452, 690–3, 696, 718, 734  
 dexamethasone acetate, 693  
 dexamethasone metasulphobenzoate,  
   693, 718  
 dexamethasone phosphate, 693  
 Dexilant, 723  
 Dexlansoprazole, 684, 718, 734  
 dextrorphan, 640  
 DF118 Forte, 723  
 dGTP, 535  
 DHC Continus, 723  
 diabetes, treatment of, 171, 287  
 diacylglycerol, 59, 64–7, 610  
 diamorphine, 1, 637  
 diarrhoea, treatment of, 460, 632–3, 638,  
   644, 653  
 diazepam, 172, 261–2, 673, 718, 734  
 dicer, 132  
 dichloroisoprenaline, 622  
 dicloxacillin, 432



- Diconal, 723  
 didanosine, 478–9, 481, 494, 718, 734  
 dideoxyadenosine triphosphate, 478–9  
 Diels-Alder reaction, 646  
 diethyl ether, 386  
 diethylstilbestrol, 537, 540  
 differentiation, 514  
 Dificlir, 723  
 Diflucan, 723  
 diflucortolone valerate, 692–3, 718, 735  
 difluoromethylornithine, 522  
 digitalin, 202  
 digitalis, 199, 202  
 digitonin, 202  
 digitoxin, 202  
 digoxin, 718, 735  
 dihydroartemisinin, 300–1, 303  
 dihydrocodeine, 633–4, 718, 735  
 dihydrocodeinone, 718, 735  
 dihydroetorphine, 645  
 dihydrofolate, 419–20, 531–3  
 dihydrofolate reductase, 96, 191, 419–20, 531  
   inhibitors, 531  
 dihydrolipoate, 96–7  
 dihydromorphine, 633–4  
 dihydropteroate, 419–20  
 dihydropteroate synthetase, 418–20  
 dihydropyran-derivatized resin, 315–17  
 dihydropyridine receptor, 112  
 dihydrotestosterone, 537  
 2,3-dimercaptopropanol, 96–7  
 Dioderm, 723  
 diphenhydramine, 661, 718, 735  
 diphenoxylate, 644, 718, 735  
 diphenylpropylamine, 643  
 diphtheria, treatment of, 423, 457  
 diphtheria toxin, 570  
 dipipanone, 644, 718, 735  
 dipole–dipole interactions, 8–9  
 diprenorphine, 645, 647  
 Diprosalic, 723  
 Diprosone, 723  
 Directed Dock, 361–2  
 dirty drugs, 194, 244  
 Discovery Studio Pro, 338  
 disoxaril, 507–8  
 displacement or inhibition curve, 117  
 displacer, 117  
 dissociation binding constant ( $K_d$ ), 116  
 dissociation constant, 388  
 distance matching, 359  
 disulphide bonds, 21–2  
 disulfiram, 89, 208, 718, 735  
 dithiolthiones, 522  
 diuretics, 94, 205, 279  
 divergent evolution, 52  
 Dixarit, 723  
 DNA, 71–6, 175  
   as a drug target, 120–31  
 DNA gyrase, 459  
 DNA ligase, 121, 128  
 DNA polymerases, 96, 477–8, 519, 535, *see also* viral DNA polymerases  
   inhibitors, 473, 535–6  
   RNA-dependent, 519  
 DNA-dependent RNA polymerase, 460  
 dobutamine, 205, 617–18, 718, 735  
 Dobutrex, 723  
 docetaxel, 137–8, 272, 529, 543, 718, 735  
 DOCK program, 358–62  
 docking, 356–66, 702  
 dolastatins, 201, 566–7  
 donepezil, 96, 603–5, 718, 735  
 dopa decarboxylase, 265, 611–12, 627  
 dopamine, 42  
   as a drug, 265  
   biosynthesis, 611–12  
   interaction with adrenergic receptors, 615  
   metabolism of, 95  
   pharmacophore, 355–6  
   prodrugs, 260, 265  
   reuptake inhibitors, 594, 629  
   role in depression, 700  
   role in Parkinsons disease, 192  
   role in treating depression, 135, 630  
   structure, 44  
 dopamine agonists, 106, 115, 205  
 dopamine antagonists, 114–15, 235, 241, 252, 258  
 dopamine receptors, 45, 50–2, 115, 189, 191–2, 194  
   regulation, 56  
 dopamine  $\beta$ -hydroxylase, 611, 627  
 dopamine  $\beta$ -monooxygenase, 627  
 dose ratio, 118  
 double-blind placebo-controlled studies, 278–9  
 doxazosin, 620–1, 718, 735  
 DOXIL, 175, 723  
 doxorubicin, 121, 175, 524–5, 568, 718, 735  
 doxorubicin analogues, 570  
 doxycycline, 453–5, 718, 735  
 Drogecil, 723  
 drug absorption, 153–5  
 drug addiction, treatment of, 639, 643, 645  
 drug administration, 168–71  
 drug alliances, 264–5  
 drug delivery, 174–7  
 drug distribution, 156–7  
 drug dosing, 171–3  
 drug excretion, 167–8  
 drug half-life, 172  
 drug load, 277  
 drug metabolism, 157–67  
 drug metabolism studies, 276–7  
 drug scavengers, 150  
 drug specifications, 286  
 drug–drug interactions, 157, 166, 195, 279, 493, 673  
   protease inhibitors, 481  
 DTIC-Dome, 723  
 dTMP, *see* deoxythymidylate  
   monophosphate  
 dTTP, *see* deoxythymidine triphosphate  
 DU-122290, 235  
 Du Pont Pharmaceuticals, 251  
 dual action serotonin and noradrenaline reuptake inhibitors, 628, 701  
 dual-reuptake inhibitors, 628  
 dual-action agents, 244  
   acting on AchE, 604–6  
 dual-action inhibitor, 551  
 duloxetine, 628, 718, 735  
 dUMP, *see* deoxyuridylate monophosphate  
 DuP-697, 234  
 duplex regions, 77  
 Durogesic, 723  
 dyflos, 600–1  
 dynamic combinatorial synthesis, 331, 333–4  
 dynamic structure–activity analysis, 670  
 dynorphins, 649–50  
 dysentery, treatment of, 462  
 Dyspamet, 723  
 dystrophin, 81
- E**
- ear drop, 452  
 ear infections, treatment of, 432, 435, 442, 452–4  
 Easi-Breathe, 723  
 ebalzotan, 287  
 Ebola virus, 468, 470  
 ecothiopate, 601  
 Ecuadorian poison frog, 201  
 ED<sub>50</sub>, 274  
 Edronax, 723  
 edrophonium, 404, 600  
 Edurant, 723  
 efavirenz, 478–81, 718, 735  
 Efcortisol, 723  
 efficacy, 116, 118  
 efflux, 428  
 Efidix, 723  
 EGF, *see* epidermal growth factor  
 Ehrlich, Paul, 413–14  
 elacridar, 523  
 Eldepryl, 723  
 Eldisine, 724  
 electric potential, 712  
 electric ray, 594  
 electronic fields, 402  
 electronic screening, 366  
 electrostatic bonds, 5, 21  
 electrostatic fields, 401  
 eleutherobin, 201, 542  
 elitist strategy, 351  
 Elocon, 724  
 Eloxatin, 724  
 emetine, 202  
 Emisphere Technologies Inc, 175  
 emtricitabine, 478–9, 481, 718, 735  
 Emtriva, 724  
 enalapril, 96, 204, 259, 295–6, 320, 718, 735  
 enalaprilate, 231, 259, 295–8  
   synthesis, 297–8  
 enantiomers, 104  
 enantiospecific reactions, 105  
 Enbrel, 724  
 end bouton, 711

- endocarditis, treatment of, 451, 453  
 endocytosis, 114, 497  
 endogenous compounds as drugs, 265–8  
 endogenous opioids, 51, 649–50  
 endometrial carcinoma, treatment of, 540  
 endomorphins, 650  
 endonucleases, 132, 526  
 endoplasmic reticulum, 77  
 endorphins, 44, 50, 190, 206, 649–50  
 endosome, 257, 496–7  
 endostatin, 566  
 Endoxana, 724  
 endozeptines, 206  
 endpoint, 279  
 energy minimization, 339, 346  
   apomorphine, 340  
 enfuvirtide, 135, 270, 478, 494–5, 718  
 enkephalinases, 96, 206, 653  
   inhibitors, 653  
 enkephalins, 190, *see also* Leu-enkephalin  
   and Met-enkephalin  
   analogues, 650–1  
   as lead compounds for enzyme  
   inhibitors, 206  
   binding interactions, 645  
   binding theories, 652–3  
   discovery of, 649  
   inactivation, 650  
   oral activity, 320  
   production of, 650  
   role in depression, 700  
   structure–activity relationships, 650–1  
   target receptors, 50, 649–51  
 enlarged thyroid gland, treatment of, 624  
 enoxacin, 458–9  
 enteric nervous system, 580  
*Enterococcus faecalis*, resistance, 462  
*Enterococcus faecium*, treatment of, 457  
 entinostat, 564  
 ephedrine, 617, 629  
 4-epi-amino-Neu5Ac2en, 502  
 epibatidine, 201, 595  
 epidermal growth factor, 54  
 epidermal growth factor receptor, 54–5,  
   548–9, 554, 559, 569  
   kinase inhibitors, 549–52, 559  
 epigallocatechin gallate, 522  
 epilepsy, treatment of, 208, 259  
 epinephrine, 609, *see* adrenaline  
 Epipen, 616  
 epipodophyllotoxin, 122, 541  
 epirubicin, 524–5, 718, 735  
 epitope mapping, 210  
 epitopes, 209–10, 243  
 Epivir, 724  
 epithilones, 542  
 epoxide hydrolase, 160–1  
 Epstein–Barr virus, 514  
 equilibrium constant, 388  
 Erb-B2 receptors, 515, 551  
 Erbitux, 724  
 erectile dysfunction and sexual  
   impotence, 204  
 eremomycin, 449–50  
 ergosterol, 144–5  
 Eribulin, 542–3, 718, 735  
 Erivedge, 724  
 erlotinib, 549, 551, 559, 564, 718, 735  
 ertapenem, 443, 718, 735  
 Erwinase, 724  
 Erymax, 724  
 Erythrocin, 724  
 erythromycin, 155, 414, 455–7, 463,  
   718, 735  
 Erythroped, 724  
 erythropoietin, 266  
*Escherichia coli*, 82, 195, 266, 413, 715  
 escitalopram, 136, 718, 735  
 Esmeron, 724  
 Esmolol, 624–6, 718, 735  
 esomeprazole, 682, 684, 686, 718, 735  
 esterases, 160, 163, 222, 256, *see also*  
   acetylcholinesterase, carboxylesterases,  
   and phosphodiesterases  
   activation of prodrugs, 258–9, 296, 473,  
   505, 637  
   drug susceptibility, 542, 643  
   resistance of penicillin methyl esters, 434  
   susceptibility of cephalosporins, 438, 440  
 esters  
   as prodrugs, 259–60  
   binding role, 222  
 Estracyt, 724  
 estradiol, 34, 109–10, 232, 528, 537–9  
 estramustine, 527–8, 530, 718, 735  
 estrogen receptor, 56, 106, 109–10, 115  
 estrogens, 169, 537, 539  
 estrone, 34, 232, 263, 539  
   lysine ester, 263  
 etanercept, 266, 719  
 ethambutol, 460–2  
 ethers, binding role, 222–3  
 ethinylestradiol, 537, 540  
 ethylene glycol, 88  
 3-ethylmorphine, 633–4  
 6-ethylmorphine, 633–4  
 etiprednol dicloacetate, 698  
 Etopophos, 724  
 etoposide, 122, 526–7, 541, 568, 719, 735  
 etorphine, 644–5, 647, 649  
 etravirine, 479–81, 719, 735  
 Etrivex, 724  
 eukaryotic cells, 415  
 Eumovate, 724  
 European Agency for the Evaluation of  
   Medicinal Products (EMA), 283  
 European Patent Convention, 281  
 European Patent Office, 281  
 evanescent wave, 197, 198  
 everolimus, 560, 719, 735  
 Evista, 724  
 evolutionary programs, 350–1  
 Ewing's tumour, treatment of, 525  
 excess sleepiness, treatment of, 282  
 Exelon, 724  
 exocytosis, 614  
 exons, 79–80  
 exotoxin A, 570  
 extended esters, 434  
 extended-spectrum agent, 552  
 extension, 409, 491, 616, 623  
   ACE inhibitors, 293, 295  
   in drug design, 231  
   opioids, 638–9  
   serotonin antagonists, 704  
 externalization, 507  
 eye diseases, treatment of, 472  
 eye drops, 451, 589, 601  
   fusidic acid, 462  
 eye infections, treatment of, 451–4, 475  
 eye lotions, 418  
 ezetimibe, 184, 719, 721, 735
- ## F
- F-13640, 255  
 F-15599, 255  
 Fabrazyme, 724  
 Fabry disease, treatment of, 266  
 facilitated transport, 168  
 fail-fast fail-cheap strategy, 195  
 false negatives, 321  
 false transmitters, 627  
 famciclovir, 473–5, 719, 735  
 famotidine, 677–9, 719, 735  
 Famvir, 724  
 Fansidar, 418, 724  
 Fareston, 724  
 Farlutal, 724  
 farnesyl diphosphate, 544–6  
 farnesyl transferase, 96, 544  
   inhibitors, 544–8  
 farnesylation, 546  
 Faslodex, 724  
 fast tracking, 284  
 Faverin, 724  
 FdUMP, 532  
 feedback control, 36  
 Femera, 724  
 fenozan, 303  
 fentanyl, 169, 172, 642–3, 649, 719, 735  
 fermentation of penicillins, 428  
 fevers, treatment of, 304  
 fexofenadine, 166–7, 719, 735  
 fialuridine, 275  
 fibrinogen, 141  
 fibroblast growth factor, 520  
 fidaxomicin, 461, 719, 735  
 fields, 344–5  
 fight or flight response, 579, 609  
 filgrastim, 267, 719  
 finasteride, 522  
 Firmagon, 724  
 first pass effect, 167  
 Fischer's lock and key hypothesis, 32  
 Fishers *F*-tests, 384  
 FK506 binding protein, 209, 560  
 FKBP12, 560  
 flagellum, 191  
 Flagyl, 724  
 flavin-containing monooxygenases,  
   160, 162

- flavopiridol, 556  
 Fleming, Alexander, 212, 421–2  
 Flexibases, 361  
 Flexible Ligands Orientated on Grid, 361  
 FlexX, 362, 364  
 Flixonase, 724  
 Flixotide, 724  
 FLOG, 361  
 Florey and Chain, 414, 421  
 Floxapen, 724  
 Floxin, 724  
 flu epidemics, 468  
 flu virus, 469  
   structure, 469  
 Fluvoxol, 724  
 flucloxacillin, 432, 719, 735  
 fluconazole, 191, 249, 254, 258, 275, 719, 735  
 Fludara, 534, 724  
 fludarabine, 534–6, 566, 719, 736  
 hydrocortisone, 690, 691  
 fludrocortisone, 692–3, 719, 736  
 flumetasone pivalate, 690–2, 719, 736  
 flunisolide, 691–2, 719, 736  
 fluocinolone acetonide, 691–2, 719, 736  
 fluocinonide, 691–2, 719, 736  
 fluocortolone, 692–3, 719, 736  
 fluocortolone caproate, 693  
 fluocortolone pivalate, 693  
 fluorine  
   as a metabolic blocker, 252–3, 550  
   as an isostere for hydrogen, 235  
   role in fluorouracil, 533  
 5-fluorodeoxyuridylate, 407–8  
 fluorometholone, 692, 695–6, 719, 736  
 fluoroquinolones, 123, 457–9  
 5-fluorouracil, 235, 530–3, 568, 719, 736  
   clinical aspects, 527, 569  
   transport into cells, 155  
 fluorouracil solid phase extraction, 323  
 fluoxetine, 136, 189–90, 719, 736  
 fluoxymesterone, 537, 540  
 fluphenazine, 260–1, 736  
 fluphenazine decanoate, 261, 719  
 flutamide, 538, 540, 719, 736  
 fluticasone furoate, 719, 736  
 fluticasone propionate, 692, 694–5, 719, 736  
 fluvastatin, 181–2, 719, 736  
 fluvoxamine, 136, 719, 736  
 FML, 724  
 folic acid, 420, 531–2  
 folinic acid, 527, 530, 533, 569  
 Folutyn, 724  
 folylpolyglutamate synthetase, 534  
 fomivirsin, 132, 475, 719, 736  
 Food and Drug Administration (FDA), 283  
 foot and mouth disease, 507  
   treatment of, 511  
 foot infections, treatment of, 443  
 force fields, 337  
 formaldehyde, 263  
 formestane, 539, 719  
 formoterol fumarate, 717  
 formulation, 173, 277  
 Fortovase, 724  
 Fortral, 724  
 Fortum, 724  
 fosamprenavir, 478, 491–2, 494, 719, 736  
 Foscan, 574, 724  
 foscarnet, 474–5, 719, 736  
 Foscavir, 724  
 fosfestrol, 537, 540  
 Fostair, 724  
 foxglove, 202  
 fragment based lead discovery, 209–10  
 fragment evolution, 210  
 fragment self-assembly, 210  
 framycetin sulphate, 718  
 FRAP, inhibition of, 560  
 Free–Wilson approach, 397, 399  
 Fries rearrangement, 619  
 frog, 595  
 fructose, 148  
*F*-test, 708  
 FTI-276, 545–6  
 FTI-277, 546  
 Fucibet, 724  
 Fucidin, 724  
 Fucidin H, 724  
 Fujisawa, 444  
 fulvestrant, 538, 540, 719, 736  
 fumagillin, 564  
 fungal nail infections, treatment of, 464  
 fungi, 716  
 Fungilin, 724  
 Fungizone, 724  
 Furadantin, 724  
 fusidic acid, 460–2, 717, 719, 736  
*Fusidium coccineum*, 461  
 fusion inhibitors, 478, 494  
 fusion protein, 266  
 Fuzeon, 724
- G**
- G cells, 660  
 GABA, see  $\gamma$ -aminobutyric acid  
 gabapentin, 719, 736  
 galantamine, 106, 199, 243, 603–4, 719, 736  
   dimers, 605  
 galanthamine, see galantamine  
 Galseud, 724  
 ganciclovir, 473, 475, 573, 719, 736  
 GAP, 67, see GTPase activating proteins  
 garlic, 574  
 gas-gangrene, treatment of, 423  
 gastric acid, 659–61, 671  
 gastric cancers, 685  
   treatment of, 533  
 gastric motility, stimulation, 265  
 gastric secretion, suppression, 589  
 gastrin, 660–1, 671  
 gastrin receptor, 660  
 gastrointestinal tract motility,  
   stimulation, 115  
 gastrointestinal infections, treatment of, 418  
 gastrointestinal stromal tumours, treatment  
   of, 559  
 gastrointestinal tract, 153–4  
   stimulation, 115, 586  
   suppressant, 588–9  
 gastrointestinal tract cancers, treatment of,  
   530, 533, 540  
 gastrointestinal tract infections, treatment of,  
   257, 459, 461  
 gatekeeper residue, 548, 551, 553–4  
 gating, 49  
 Gaucher's disease, treatment of, 266  
 G-coupled receptors, dimerization, 53  
 GDP, see guanosine diphosphate  
 gefitinib, 249, 253, 549–51, 559, 719, 736  
 gel electrophoresis, 26  
 gelatinases, 561  
 gemcitabine, 534–6, 719, 736  
 gemtuzumab, 569, 571, 719  
 Gemzar, 724  
 Genasense, 724  
 gene silencing, 564  
 gene therapy, 81, 175, 511, 568, 572–3  
 gene transcription control, 56  
 gene-directed enzyme prodrug therapy  
   GDEPT, 572–3  
 general anaesthetics, 1, 143, 167, 170, 386  
 General Medical Council, 284  
 genetic algorithms, 350–1, 366  
 genetic diseases, 36, 79–81, 132  
 genetic engineering, 81–3  
 genetic fingerprinting, 280, 522  
 genetic polymorphism, 35, 56, 76  
 genistein, 522  
 genital herpes, 468  
   treatment of, 470, 472, 475  
 genital infections, treatment of, 454  
 genital warts, treatment of, 474, 511, 543  
 genomic research, viral diseases, 471  
 genomics, 26  
 Genta, 271, 529  
 gentamicin, 426, 453, 719, 736  
 Gentacin, 724  
 Gentisone, 724  
 geranylgeranyl diphosphate, 546  
 geranylgeranyltransferase, 546  
 Gilead Sciences, 505  
 Ginko, 212  
 glaucoma, 169, 586  
   treatment of, 115, 586, 598, 601, 611, 624  
 Glaxo pharmaceuticals, 676, 678  
 GlaxoWellcome pharmaceuticals, 494, 502  
 Gleevec, 552  
 Gliadel, 171, 724  
 Glivec, 552, 724  
 global energy minima, 346  
 glomerulus, 168  
 glucagon, 63  
 glucarpidase, 266, 719  
 glucocorticoid agonist, 378  
 glucocorticoid receptor, 106  
 glucocorticoids, 106, 537, 689–700  
 glucose, 36–7, 39, 60–2, 148, 320, 610  
 glucose-1-phosphate, 36–7, 39, 61–2  
 $\beta$ -glucuronidase, 571–2  
 glucuronidation, 165  
 C-glucuronides, 162

- N-glucuronides, 162  
 O-glucuronides, 162  
 S-glucuronides, 162  
 glucuronyltransferase, 163  
 glutamate (glutamic acid), 17, 21–2,  
     705, *see also* polyglutamate and  
     polyglutamylation  
     acetylcholinesterase active site, 597  
     acid-catalyst in enzyme mechanisms, 180  
     carboxylation of prothrombin, 25  
     catalyst in enzyme mechanisms source, 33  
     kinase active site, 553–4, 558  
     matrix metalloproteinase active site, 561  
     neuraminidase active site, 499, 503, 505–6  
     neurotransmitter, 44  
     role in depression, 700  
 glutamate receptors, 50–1  
 glutamic acid, *see* glutamate  
 glutamine, 17, 162, 545, 705  
 glutathione, 162, 260  
 glutathione conjugates, 162, 165–6  
 glutathione S-transferase, 160, 162, 165  
 glyceryl trinitrate, 169, 207  
 glycine, 705, 712  
     as neurotransmitter, 44  
 glycine receptor, 48  
 glycoconjugates, 148  
 glycogen, 36–9, 60–2, 148, 610  
 glycogen synthase, 39, 61–2  
 glycogen-1-phosphate, 38  
 glycolipids, 148  
 glycomics, 148  
 glycoproteins, 4, 148, *see also* bleomycins,  
     gp40, gp120, P-glycoprotein,  
     neuraminidase, haemagglutinin  
 glycosidases, 495  
 glycosylase, 448  
 glycosylation, 25  
 glycyrrhetic acid, 687  
 glycyrrhizin, 687  
 GNF-2, 555  
 GOLD, 366  
 gonadotrophin-releasing hormone, 537, 581  
     antagonist of, 566  
 gonorrhoea, treatment of, 435, 442, 459  
 Good Clinical Practice GCP, 284  
 Good Laboratory Practice GLP, 284  
 Good Manufacturing Practice, 284  
 goserelin, 270–1, 537, 540, 719  
 gout, treatment of, 96, 136  
 gp41 glycoprotein, 476–7, 494–5  
 gp120 glycoprotein, 476–7, 495  
 G-protein coupled receptors, 50–2, 54, 56,  
     58–9, *see also* adrenergic receptors,  
     opioid receptors, muscarinic receptors,  
     histamine receptors, dopamine  
     receptors, calcium sensing receptor,  
     rhodopsin, serotonin receptors  
 G-proteins, 50–1, 58–64, *see also* small  
     G-proteins  
 gramicidin, 145, 452, 718  
 gramicidin S, 257  
 Gram-negative bacteria, 715  
 Gram-positive bacteria, 715  
 Gram-stain, 715  
 granisetron, 192, 206, 719, 736  
 granzyme, 518  
 grapefruit juice, 166  
 Grb2 protein, 67–8  
 grey baby syndrome, 280, 454  
 grid program, 344–5, 361, 401, 404, 407,  
     501–2  
 Grignard reaction, 646  
 GRIND, 404  
 group shift, 253–4  
     serotonin antagonists, 702  
 GROW, 377  
 growth factors, 54, 67–68, 517–18  
 growth hormone receptor, 54–5  
 GS 4071, 505  
 GTPase activating proteins, 67  
 guanethidine, 627–8, 719, 736  
 guanine, 71–2  
     alkylation of, 126  
     metallation of, 126  
     nucleophilic groups, 124  
 guanine nucleotide exchange factors, 67  
 guanosine diphosphate, 58–60, 64, 67–8  
 guanosine triphosphate, 38, 58–60, 64, 67–8  
 guanyl transferase, 510  
 guanylate cyclase, 67–8  
 N<sup>α</sup>-guanylhistamine, 664  
 Guardia infections, treatment of, 462  
 Gulf War syndrome, 600  
 gut infections, 413  
     treatment of, 418, 451  
 gynaecological infections, treatment of, 443
- H**
- H77/67, 683  
 H124/26, 683  
 H159/69, 683  
 H<sup>+</sup>/K<sup>+</sup>-ATPase, *see* proton pump  
 Haelan, 724  
 haem, 539  
 haemagglutinin, 469, 496–8  
 haematological malignancies,  
     treatment of, 525  
 haemoglobin, 23, 301–2, 573  
 haemophilias, 80  
*Haemophilus epiglottis*, treatment of, 442  
*Haemophilus influenzae*, 440, 442, 715  
     treatment of, 443, 457  
 haemoproteins, 158  
 haemorrhagic cystitis, 530  
 haemorrhagic fevers, treatment of, 470, 510  
 haemorrhoids, treatment of, 299  
 Halaven, 724  
 halichondrin B, 201, 542–3  
 halobetasol propionate, 692–3, 719, 736  
 haloperidol, 164  
 halothane, 386  
 HAMA response, 267  
 Hammerhead, 364–6  
 Hammett equation, 668  
 Hammett substituent constant,  
     388–90, 668  
 Hansch equation, 392–3  
 hard drugs, 167  
 HASL, 404  
 hay fever, treatment of, 661  
 HCV NS3-4A protease, 508–9  
     inhibition of, 509  
 HDM2 protein, 142–3, 519  
 head cancers, treatment of, 530, 534,  
     569, 574  
 heart irregularities, treatment of, 116  
 heavy metals, 96  
 hedgehog signalling pathway, 556, 560  
 helicases, 75  
     inhibition, 524  
*Helicobacter pylori*, 659, 685–7  
     cause of cancer, 514  
 α-helix, 18–19  
 heme, 302  
 Henderson–Hasselbalch equation, 154  
 hepatitis, 170  
 hepatitis A, 468, 507  
 hepatitis B, 81  
     cause of cancer, 514  
     treatment of, 471, 479, 481, 511  
 hepatitis C, 81, 508  
     treatment of, 267, 471, 508–11  
 hepatitis E, 468  
 hepatocytes, 195  
 Hepsera, 724  
 HER2 receptor, 551, 559, 569  
 HER3, 559  
 HER4, 559  
 herbal medicines, 212–13, 603–4, 687  
 herbicides, 2  
 herceptin, 522, 569, 724  
 HERG potassium ion channels, 193, 275  
 heroin, 1, 170, 637, 639  
 herpes infections, treatment of, 475  
 herpes keratitis, treatment of, 475  
 herpes simplex  
     life cycle, 470  
     treatment of, 454  
 herpes simplex encephalitis,  
     treatment of, 475  
 herpes simplex virus, 573  
 herpes viruses, 472, 475  
 Herpid, 724  
 hetacillin, 264  
 heterocodeine, 633–4  
 heterocycles  
     binding interactions, 224–5  
     binding role, 223  
 hexamine, *see* methenamine  
 hexobarbitone, 259–60  
 hexyl-insulin monoconjugate 2, 175  
 Hidrasec, 724  
 Higgins, Jack, 589  
 high blood pressure, treatment of, 622  
 high density lipoproteins, 178  
 high throughput screening, 197, 321  
 highly active antiretroviral therapy  
     (HAART), 478  
 high-throughput screening, 196  
 HINT, 404

- Hippocrates, 566  
 Hiprex, 724  
 histamine, 341–2, 660–5, 668–9, 671  
 histamine antagonists, 659–62, 664–8, 670–9, *see also* antihistamines  
 histamine receptors, 50, 115, 660–2  
   evolution, 52–3  
 histidine, 17, 21–2, 180, 705  
   acid/base catalyst, 33–4, 179, 190, 597–9  
   Ames test, 194  
   catalytic triad, 34, 90  
   chymotrypsin, 34–5  
   lipase active site, 90  
 histidine kinases, 548  
 histone acetylase, 564  
 histone deacetylase, 96, 564  
   inhibitors, 564  
 histones, 76, 564  
 HIV, 471, 477  
   antiviral therapy, 477–8  
   cause of cancer, 514  
   life cycle, 476–7  
   structure, 476–7  
   treatment of, 470  
 HIV protease, 20, 28, 143, 480–3  
   cloning, 195  
   role in the viral life cycle, 477  
   target in HIV therapy, 477–8  
 HIV protease inhibitors, 480–94  
   drug–drug interactions, 462  
   in HIV therapy, 478  
 HIV protease substrates, 482–3  
 Hivid, 724  
 HMG-CoA, 33, 96, 178–9, 182–3  
 HMG-CoA reductase, 33, 96, 178–80, 183–4, 546  
 HMGR, *see* HMG-CoA reductase  
 Hodgkin's disease, 514  
   treatment of, 522, 530  
 Hodgkin's lymphoma, treatment of, 530, 569  
 Hodgkins, Dorothy, 422  
 Hofmann elimination, 593  
 homology modelling, 367, 702  
 honey, 413  
 Hong Kong flu, 496  
 hormone-based therapies, 536–40  
 hormones, 42, 44  
   as drugs, 266–7  
 HR780, 238  
 HSP90, 28  
 HSV, treatment of, 475  
 human ether-a-go-go related gene, 193  
 human genome project, 26, 82  
 human granulocyte-colony stimulating factor, 267  
 human growth factor, 82, 141, 266  
 human growth hormone, 175  
 human growth hormone antagonist, 267  
 human immune deficiency virus, *see* HIV  
 human intestinal di-/tripeptide transporter, 473  
 human intestinal proton-dependent oligopeptide transporter, 473  
 human parathyroid hormone, 266  
 human rhinovirus, 507  
 Humira, 724  
 hunger suppression, 629  
*Huperzia serrata*, 604  
 huperzine A, 604  
 huperzine B dimers, 605  
 hybrid drugs, 244  
 hybridomas, 267  
 Hycamptin, 724  
 Hycamtin, 724  
 hycanthone, 309  
 Hycodan, 724  
 Hydantoins, solid phase synthesis, 318  
 hydrocodone, 719, 736  
 hydrocortisone, 452, 689, 693, 698–9, 719, 736  
   sustained release, 698–9  
 hydrocortisone acetate, 693, 696, 719, 736  
 hydrocortisone butyrate, 693, 719, 736  
 hydrocortisone phosphate, 693  
 hydrocortisone succinate, 693  
 hydrogen bond acceptor, 6  
 hydrogen bond donor, 6  
 hydrogen bond flip-flop, 6  
 hydrogen bonding, 6–8, 21–2  
 hydrolases, 36  
 hydromorphone, 633–4, 719, 736  
   formulation, 173  
 hydrophobic interactions, 10, 22  
 hydrophobicity, 385  
 3-hydroxy-3-methylglutaryl coenzyme A, 178  
 3-hydroxy-3-methylglutaryl-coenzyme A reductase, *see* HMG-Co reductase  
 4-hydroxyandrostenedione, *see* formestane  
 hydroxycarbamide, 96, 534–5  
 17 $\alpha$ -hydroxylase-17(20)-lyase, inhibition of, 538  
 hydroxylation  
   drug metabolism, 160, 164, 684  
   metabolic inhibitors, 539  
   of proline, 25  
   vancomycin biosynthesis, 446–7  
 4-hydroxyminaprine, 205  
*N*-(2-hydroxypropyl)methacrylamide, 174  
 7-hydroxystaurosporin, 556  
 17 $\beta$ -hydroxysteroid dehydrogenase type 1, 34, 206, 232, 244  
 4-hydroxytamoxifen, 538  
 5-hydroxytryptamine, 205–6, *see* serotonin  
 hyoscyne, 202, 588, 719, 736  
 hyoscyamine, 588  
 Hyperchem, 338  
 hyperpolarization, 712–13  
 hypertension, 192  
   treatment of, 611, 617, 620, 624–5, 627  
 hypodermic syringe, 632  
 hypoglycaemia, 203  
 Hypovase, 724  
 hypoxia, 520  
 hypoxia-activated prodrug, 528  
 hypoxia-inducible factors, 520  
 Hytrin, 724  
 ibritumomab, 569–70, 719  
 ibuprofen, 212, 522  
 IC<sub>50</sub> value, 117  
 ICI-D7114, 287–8  
 idamycin, 524  
 idarubicin, 524–5, 719, 736  
 idoxuridine, 471, 473–5, 719, 736  
 IFN-alpha, 511  
 ifosfamide, 527–8, 530, 719, 736  
 imatinib, 231, 284, 522, 549, 552–4, 559, 719, 737  
 imidazole ring, as a zinc ligand, 546  
 imiglucerase, 266, 719  
 Imigran, 724  
 imipenem, 443, 719, 737  
 imipramine, 208, 627–8, 719, 737  
 imiquimod, 475, 511, 719, 737  
 Immukin, 724  
 immunoglobulin E, 267  
 immunomodulators, 471, 511, 565  
 immunostimulants, 566  
 immunosuppressants, 140, 208, 260, 565  
 Imodium, 644, 724  
 implants, 171  
 importance sampling, 348  
 impurity profiling, 289  
 Imuran, 724  
*in vitro* testing, 195  
*in vivo* testing, 195–6  
 Inavir, 724  
 Incas, 169, 629  
 Incivek, 724  
 indacaterol, 620, 719, 737  
 indanyl carbenicillin, 433, 435  
 Inderal, 725  
 Indian cobra, 594  
 indicator variable, 397, 399  
 indinavir, 12, 164, 478, 489–90, 493–4, 719, 737  
   metabolism of, 164  
 indometacin, 93, 95, 719, 737  
 indomethacin, *see* indometacin  
 induced dipole interactions, 9, 221  
 induced fit, 45  
 infliximab, 268, 719  
 influenza, 468  
 influenza A, treatment of, 471  
 influenza virus structure and life cycle, 496–8  
 inhibition or inhibitory constant, 98, 117  
 Innovace, 725  
 inosine, 535  
 inosine-5'-monophosphate dehydrogenase, 510  
 inositol, 66  
 inositol triphosphate, 59, 64–7, 595, 610  
 insect bites, treatment of, 661  
 insecticides, 390, 601–2  
 Institutional Review Board, 284  
 insulin, 28, 266  
   administration, 153, 171  
   control of glycogen synthesis, 39



- insulin (*Continued*)  
 crossing the blood brain barrier, 157  
 dosing regimes, 171  
 oral delivery system, 175  
 production of, 82
- insulin receptor, 54–5
- integrase, 476–7  
 inhibitors, 478, 494–5
- integrins, 140–1, 520–1
- Intelence, 725
- intercalating agents, 120–1, 524–5
- interferons, 266–7, 510–11, 566, 719
- interleukins, 520, 566
- intermolecular bonds, 4
- International Preliminary Examination Report, 281
- International Search Report, 281
- intestinal infections, *see* gastrointestinal infections
- intracellular receptors, 55–6
- intramolecular bonds, 4, 21
- intramuscular injection, 170
- intraperitoneal injection, 171
- intrathecal injection, 171
- intravenous drip, 170
- intravenous injection, 170
- intra vitreal injection, 475
- intron, 79–80
- IntronA, 725
- Invanz, 725
- inverse agonists, 112–13
- Investigational Exemption to a New Drug Application (IND), 283
- Invirase, 725
- ion carriers, 146
- ion channel disrupters, 498
- ion channels, 47–9  
 ligand gated, 49  
 voltage gated, 49
- ion–dipole interactions, 8–9
- ionic bonding, 5, 21–2
- ionophores, 147
- iontophoresis, 170
- IP<sub>3</sub>, *see* inositol triphosphate
- ipecacuanha, 202
- ipratropium, 589, 719, 737
- Ipratropium Steri-Neb, 725
- iproniazid, 629–30
- Iressa, 550, 725
- irinotecan, 272, 526–7, 529, 569, 572–3, 719, 737
- irregular heart rhythms, treatment of, 627
- irreversible enzyme inhibitors, 89–90
- Isentress, 725
- Isis/Draw, 338
- Ismelin, 725
- isoetharine, 618
- isoleucine, 17, 22, 705  
 HIV protease, 483, 485, 487, 490–2  
 kinase mutation, 555  
 matrix metalloproteinase inhibitors, 561  
 mimic, 140  
 Ras protein, 545
- isoleucyl tRNA synthetase, 464
- isomerases, 36, *see also* topoisomerases
- isoniazid, 164, 203, 208, 414, 453, 460–2
- isonicotinaldehyde thiosemicarbazone, 203
- isoprenaline, 229, 616, 618, 621–2
- isosteres, 225–6, 234–6, 252
- isothermal titration calorimetry, 198
- isoxazolyl penicillins, 432
- isozymes, 39, 93, 95, 191
- Istodax, 725
- ## J
- Jakafi, 725
- Jenner, 470
- JM-216, 529
- JM-3100, 495
- John Hopkins Clinical Compound Library, 203
- Joicela, 725
- joint infections, treatment of, 457, 459
- Joubert, 421
- ## K
- Kaletra, 725
- kanamycin, 464–5
- Kaposi's sarcoma, 514  
 treatment of, 472
- Katek, 725
- Kefadim, 725
- Keflex, 725
- Keflin, 725
- Keftab, 725
- Kefurox, 725
- Kemicetine, 725
- Kenalog, 725
- ketanserlin, 115, 344, 369
- ketobemidone, 642
- ketoconazole, 481
- ketones, binding role, 218
- kidney cancer, treatment of, 540, 559
- kidneys, 167–8
- killer nanotubes, 145–6
- kinase-linked receptors, 53–5, 66
- kinases, *see* protein kinases, serine–threonine kinases and tyrosine kinases
- Klaricid, 725
- Koch, 413
- Koshland's theory of induced fit, 32
- Kytril, 725
- ## L
- L-685434, 489–90
- L-704486, 489–90
- L-739750, 545–6
- L-744832, 546
- L-787257, 255
- L-791456, 255
- L-PAM, *see* L-phenylalanine mustard
- labetalol, 620–1
- $\beta$ -lactamases, 422, 427–8, 463, 570, 572  
 inhibition of, 92, 444–5
- $\beta$ -lactams  
 as acylating agents, 221  
 binding role, 221
- lactate dehydrogenase, 30, 32, 35–6, 39
- lactic acid, 30, 35–6, 39
- ladostigil, 244
- lamitidine, 678
- lamivudine, 478–9, 481, 719, 737
- lanalidomide, 565
- laninamivir, 502, 719, 737
- laniquidar, 523
- Lanoxin, 725
- lansoprazole, 96, 680–2, 685, 719, 737
- Lanvis, 725
- lapatinib, 285, 551–2, 557, 559, 719, 737
- Largactil, 725
- lasalocid A, 147
- Lassa fever, 468  
 treatment of, 510
- laudanum, 632
- laxative, 202
- LD<sub>50</sub> value, 274
- L-dopa, *see* levodopa
- LDZ, 262
- lead compound, 199
- lecithin, 3
- leg ulcers, treatment of, 462
- LEGEND, 377
- legionnaires disease, treatment of, 457, 462
- Lemsip, 617
- lenalidomide, 565, 719, 737
- Lentaron, 725
- leprosy, treatment of, 420, 462, 565
- leptospirosis, treatment of, 423
- Lescol, 725
- letrozole, 539–40, 719, 737
- leucine, 17, 22, 705  
 interaction with capsid binding agents, 508  
 interaction with statins, 183  
 mimic, 140  
 Ras protein, 545
- leucine tRNA synthetase, 464
- leucovorin, 527, 533, 569
- Leu-enkephalin, 174, 649, 651
- leukaemia, 468, 514, 567
- leukaemia treatments  
 alkylating agents, 530  
 antibodies, 569  
 antibody–drug conjugates, 571  
 antimetabolites, 533–5  
 arsenic trioxide, 566  
 asparaginase, 267, 567  
 hormone-based, 540  
 intercalating agents, 525  
 kinase inhibitors, 555, 559  
 6-mercaptopurine, 90, 534  
 methotrexate, 171, 533  
 pegaspargase and pegademase, 267  
 vinca alkaloids, 543
- Leukeran, 725
- leuprolide, 537, 540
- levabuterol, 619, 719, 737
- levallorphan, 641
- Levaquin, 725
- levobupivacaine, 282–3, 719, 737
- levodopa, 95, 155, 260, 265, 611–12, 719, 737

- levofloxacin, 459, 719, 737  
levorphanol, 640–1  
levothyroxine sodium, 169  
Levulan, 725  
lewisite, 96  
Lexiva, 725  
LHRH, *see* luteinizing hormone-releasing hormone  
Librium, 260, 725  
lice, treatment of, 602  
lidocaine, 170, 252, 673, 719, 737  
ligand efficiency, 211  
ligand-gated ion channels, 712  
ligases, 36, 81–2  
lignans, 540  
lignocaine, *see* lidocaine  
Lilly Pharmaceuticals, 439, 490, 678  
lincomycin, 455–6  
lincosamides, 455–7  
linear regression analysis, 383–4  
Lineweaver–Burk plots, 40–1, 97–9  
linezolid, 456–7, 719, 737  
linkers (combinatorial synthesis), 314–17  
linoleate, 178  
lipase enzymes, 62  
lipid carrier, 445  
Lipinski's rule of five, 154–5, 211, 319, 320  
Lipitor, 725  
lipophilic efficiency, 226  
liposomes, 174–5, 520, 525, 574  
5-lipoxygenase, 96  
lipstatin, 200–1  
liquorice, 687  
lisinopril, 155, 204, 296, 719, 737  
Liskonum, 725  
Lister, 413  
lithium carbonate, 719  
lithium salts, 66  
liver cancers, 514  
liver microsomal fractions, 277  
local anaesthetics  
  ability to cross cell membranes, 156  
  administration, 153, 170  
  development of, 237, 252  
  localization of action, 265, 611, 616  
  long lasting, 282  
  molecular target, 49, 594  
  structure comparisons, 351  
  testing methods, 196  
local energy minimum, 346  
Locoid, 725  
Locorten-Vioform, 725  
log *P*, 248, 385–7  
lollipop phase separator, 324  
lomustine, 124, 126, 530, 719, 737  
lonafarnib, 96, 546, 548  
London forces, 8  
look-up tables, 361  
loperamide, 464, 644, 719, 737  
lopinavir, 264, 478, 485, 488–9, 494, 720, 737  
Lopresor, 725  
losartan, 251, 720, 737  
Losec, 682  
Lotemax, 725  
loteprednol, 737  
loteprednol etabonate, 692, 697, 720, 737  
Lotriderm, 725  
lovastatin, 181, 200, 238, 720, 737  
low density lipoprotein receptors, 178, 184  
low density lipoproteins, 133, 178  
loxtidine, 678  
lucanthon, 305, 308–9, 720, 737  
Lucentis, 725  
LUDI, 371–4  
lumiracoxib, 280, 720, 737  
lung cancer, 522  
  treatment of, 527, 530, 534, 543, 559  
lupus, treatment of, 268  
Lustral, 725  
luteinizing hormone, 537  
luteinising hormone-releasing hormone (LHRH), 537  
  agonists, 537–8, 540  
LY-333328, 449–50  
lyases, 36  
Lyme disease, treatment of, 423, 435, 442, 454, 457  
lymecycline, 454  
lymphomas, 514, *see also* Burkitt's lymphoma  
  treatment with alkylating agents, 530  
  treatment with antibodies, 569, 570  
  treatment with antimetabolites, 533, 534  
  treatment with drugs acting on tubulin, 543  
  treatment with histone deacetylase inhibitors, 564  
  treatment with hormone-based therapies, 540  
  treatment with intercalators, 525  
lysine, 17, 21–2, 705  
  ACE active site, 296  
  acetylation, 564  
  antibodies, 569  
  as a nucleophilic group, 35  
  carbamoylation, 124  
  HMG-CoA active site, 179  
  in prodrugs, 262–3  
  insulin, 175  
  killer nanotubes, 146  
  mutation in neuraminidase, 506  
  safety-catch acid-labile linker, 329  
  transpeptidase active site, 429  
lysis, 415, 423  
lysosomes, 469  
Lysovir, 725
- M**
- MabCampath, 725  
MabThera, 725  
Macfarlane and Co, 632  
Macfarlane-Smith, 632  
Macrobid, 725  
Macrochantin, 725  
macrolides, 414, 452, 455, 457  
macromolecules, 4  
Macugen, 725  
Madagascar periwinkle plant, 540  
magainins, 145, 201  
magic bullet, 413  
ma-huang, 617  
maize, 3  
malaria, 189, 299  
  treatment of, 418, *see also* antimalarial agents  
malathion, 601–2, 720, 737  
male erectile dysfunction, treatment of, 96  
malignant cancer, 514, 521  
Manerix, 725  
manic depressive illness, 66  
Mansil, 725  
manual docking, 356  
Map kinase, 68  
maraviroc, 194, 495, 720, 737  
Marcaine, 725  
marijuana, 170  
marimastat, 562  
marine cone snail, 202  
marine sea hare, 566  
marine worms, 566, 603  
Marketing Authorization Application, 283  
marshmallow, 687  
mass spectrometry, 26  
  structure determination, 212  
matrix (M2) protein, 498  
matrix metalloproteinases, 96–7, 520–1, 561  
  inhibitors, 561–3  
Maxidex, 725  
Maxitrol, 725  
Maxolon, 725  
May apple, 540  
Mayan, 202  
maytansine 1, 541  
maytansinoids, 541, 570  
MCDOCK, 366  
MDAN-21, 655  
MDM2 protein, 142–3  
me too drugs, 181, 203, 233  
measles, 468  
  treatment of, 470  
me-better drugs, 181, 203, 233  
mechanism-based inhibitors, 92  
medical folklore, 202  
Medicines for Children Research Network, 280  
Medicines for Malaria Venture, 189  
Medrone, 725  
medroxyprogesterone acetate, 537, 540, 720, 737  
mefloquine, 299  
Mefoxin, 725  
Megace, 725  
megestrol acetate, 252, 537, 540, 720, 737  
Mek protein, 68  
melanin, 80, 528  
melanin-concentrating hormone, 700  
melanin-concentrating hormone receptor, 194  
melanoma, 517  
  treatment, 528–30  
melarsoprol, 465, 466

- melphalan, 527–8, 530, 720, 737  
 membrane potential, 49  
 membrane tethers, 257–8  
 membrane type metalloproteinases, 561  
 memory loss, treatment of, 116  
 meningitis  
   prophylactic, 442  
   treatment of, 442–3, 453  
 meningococci, penicillin resistant, 462  
 meperidine, *see* pethidine  
 mephedrone, 616  
 S-mephenytoin hydroxylase (CYP2C19), 682  
 mepyramine, 661  
 meraviroc, 495  
 6-mercaptopurine, 90, 260–1, 534, 536,  
   720, 737  
 mercapturic acid conjugates, 165  
 mercapturic acids, 162  
 Merck pharmaceuticals, 12, 181, 279, 489, 491  
 mercury nitrate, 96  
 mercury poisoning, 96  
 Meronem, 725  
 meropenem, 443, 720, 737  
 Merrifield peptide synthesis, 314, 317  
 mesna, 528, 530, 720  
 message-address concept, 650, 653–4  
 messenger RNA (mRNA), 76–80  
   target in antisense therapy, 132–3, 493–4  
   translation, 77–9, 452  
   viral, 469, 497, 510  
 Mestinon, 725  
 metabolic blockers, 252, 551  
 metabolically susceptible groups, 255–6  
 metallating agents, 125–6, 529–30  
 metamaminol, 627  
 metastasis, 514–15, 520–1, 561  
 metazocine, 641  
 Met-enkephalin, 17–18, 649–50  
 methacholine, 585  
 methadone, 643–4, 649, 720, 738  
   pharmacophores, 228  
 Methadose, 725  
 methamphetamine, 169–70  
 methenamine, 263, 460–2, 720  
 methicillin, 431–2, 462  
 methicillin-resistant *Staphylococcus aureus*,  
   *see* MRSA  
 methionine, 17, 22, 705  
   Ras protein, 545  
 methionine aminopeptidase, 564  
 methisazone, 511  
 methoctramine, 606  
 methotrexate, 96, 155, 157, 171, 224, 266,  
   531–3, 568  
 2-methoxyestradiol, 244  
 6-methoxypenicillin, 425  
 methyl mercury, 96  
 N-methyl transferase, 611  
 N-methyl-D-aspartate antagonists, 116  
 4-methylburimamide, 669  
 $\alpha$ -methyl dopa, 627, 720, 738  
 methylene shuffle, 250  
 N<sup>5</sup>, N<sup>10</sup>-methylene tetrahydrofolate, 407,  
   531–3  
 4-methylhistamine, 663  
 N-methylmorphinan, 640–1  
 $\alpha$ -methylnoradrenaline, 616–17, 627  
 6-methylpenicillin, 425  
 methylphenidate, 629, 720, 738  
 methylprednisolone, 690–3, 720, 738  
 methylprednisolone acetate, 693  
 methylprednisolone succinate, 693  
 methyltransferases, 162, 166  
 $\alpha$ -methyl-*m*-tyramine, 627  
 $\alpha$ -methyltyrosine, 626–7  
 $\alpha$ -methyl-*m*-tyrosine, 627  
 metiamide, 669–70  
 metoclopramide, 192, 265, 720, 738  
 metoprolol, 625, 720, 738  
 Metosyn, 725  
 metrifonate, 603–4  
 Metrolyl, 725  
 metronidazole, 423, 460–2, 659, 686, 720, 738  
 Metropolis method, 348, 349, 350, 366  
 Mevacor, 725  
 mevaldehyde, 179–80  
 mevaldyl CoA, 179–80, 183  
 mevalonate, 178–80, 184  
 mevastatin, 180–1, 718, 725  
 mevinolin, 181, 238  
 mezlocillin, 435  
 Michaelis constant, 40, 98  
 Michaelis-Menten equation, 39  
 miconazole nitrate, 719  
 microchips  
   implantable, 171  
 microfluidics, 321, 325, 327  
 micro-RNA, 132–3  
 micro-RNA-protein, 133  
 microsomes, 195  
 microspheres, 175, 540  
 microtubules, 26–7, 136–7, 522, 539–41  
   as a drug target, 525, 541–2  
 microwave technology, 322–3, 325–6  
 Mictral, 725  
 Migraine, treatment of, 189, 265, 624  
 Mildison, 725  
 milk thistle, 687  
 minaprine, 205  
 mineralocorticoids, 689  
 minipumps, 171  
 minocycline, 454, 464  
 miotine, 599  
 mirasan, 305–6, 309–10  
 Mircel D, 725  
 miRNA, *see* micro-RNA  
 miRNP, *see* micro-RNA protein  
 mirtazepine, 621, 720, 738  
 miscoding, 124  
 mitogen-activated protein kinase, 67  
 mitomycin C, 127–8, 530  
 MitoQ, 257  
 mitotane, 539–40  
 Mitoxana, 725  
 mitoxantrone, 524–5, 720, 738  
 Mivacron, 725  
 mivacurium, 592, 594, 720, 738  
 mix and split combinatorial synthesis, 328–9  
 mixed enzyme inhibition, 90  
 MM-13902, 445  
 MMR vaccine, 470  
 moclobemide, 96, 629–30, 720, 738  
 modafinil, 282, 725, 738  
 Modecate, 725  
 Modrasone, 725  
 modulators, 206  
 molar refractivity, 391  
 molecular dynamics, 346–7  
 molecular electrostatic potentials, 342–3  
 molecular mechanics, 337  
 molecular modelling, 207, 215, 227–8,  
   241–3, *see also* structure-based drug  
   design and *de novo* drug design  
   colchicine, 405  
   thymidylate kinase inhibitors, 407–10  
 molecular orbitals, 343–4  
 mometasone, 738  
 mometasone furoate, 692, 695–6, 720, 738  
 monensin A, 147  
 monoamine hypothesis, 700  
 monoamine oxidase, 89, 95, 160, 162, 205,  
   612, 627  
   inhibitors, 89, 95–6, 208, 244, 629–30, 700  
 monoaminergic hypothesis, 700  
 monobactams, 444  
 monoclonal antibodies, 568  
 monomethyl auristatin E, 569  
 mononucleosis, treatment of, 472  
 monooxygenases, 158  
 monosaccharides, 148  
 Monotrim, 725  
 Monte Carlo algorithms, 348–50, 366  
*Moraxella catarrhalis*, 442  
 Morcap, 725  
 morning dip, 620  
 Morphesic, 725  
 morphinans, 640–1  
 morphine, 1–2, 164, 632–9, 64–45, 647,  
   649–50, 653, 720, 738  
   N-methylquaternary salt, 637  
   pharmacophores, 228  
 motion sickness, treatment of, 115, 588  
 motor nerves, 579  
 motor nervous system, 578–9  
 mouth infections, treatment of, 442  
 movement disorders, treatment of, 589  
 moxifloxacin, 459, 720, 738  
 mRNA, *see* messenger RNA  
 MRSA, 432, 441  
   treatment of, 446, 452, 457, 462, 464  
 MS-275, 564  
 MST Cintinus, 725  
 MS-Whim, 404  
 mTOR kinase, 560  
   inhibition of, 560  
 mucous membrane infections, treatment  
   of, 418  
 multidrug resistance, 523  
 multi-kinase inhibitors, *see* multi-tyrosine  
   receptor kinase inhibitors  
 multiple myeloma, treatment of, 530, 563, 566  
 multiple sclerosis, treatment of, 2, 268

- multiple-target directed ligands, 605  
 multi-target drug discovery, 243–5  
 multi-targeted agents, 193, 195  
   for AChE and M2, 606–7  
 multi-tyrosine receptor kinase inhibitors,  
   556–8, 560  
 mumps, 468  
   treatment of, 470  
 mupirocin, 464, 720, 738  
 muscarine, 199, 582, 584–5  
 muscarinic agonists, 115–16, 238, 585–7  
 muscarinic antagonists, 115, 205, 587–90  
 muscarinic receptor, 50–1, 53  
   binding site, 583–5  
   evolution, 52  
   in the peripheral nervous system, 579  
   location, 582  
   presynaptic, 613  
   regulation of, 56  
   signal transduction, 62–3, 595  
   subtypes, 52, 115, 582, 595  
 muscle relaxant, 115  
 muscle spasm, treatment of, 202  
 muscular dystrophy, 81  
   treatment of, 132  
 mushroom, 582  
 mustard, 3  
 mustard gases, 124, 207  
 mutagen, 514  
 mutagenesis studies, 614  
 mutations, 350, 428, *see also* genetic  
   polymorphism, genetic diseases  
   Ames test, 194  
   cancer, 514–15, 567  
   drug resistance, 241, 428, 462, 523  
   drug resistance-flu virus, 498, 506  
   drug resistance-fluoroquinolones, 459  
   drug resistance-HIV, 477, 479–80, 489, 492  
   drug resistance-kinase inhibitors, 555  
   drug resistance-penicillins, 432  
   drug resistance-sulphonamides, 420  
   drug resistance-topoisomerase  
   poisons, 527  
   drug resistance-tubulin binders, 543  
   drug resistance-viral DNA polymerase  
   inhibitors, 475  
   evolution of enzymes, 31, 420  
   genetic algorithms, 350–1, 366  
   mutating agents, 510  
   protein studies, 82–3  
   Ras proteins, 67, 544  
   selectivity of ion channels, 48  
   viruses, 470, 477, 499  
 MXL, 725  
 myalgia, 181  
 myasthenia gravis, treatment of, 96, 586,  
   599–600  
*Mycobacterium tuberculosis*, 463  
 Mydriacyl, 725  
 Mydrilate, 725  
 myelin sheaths, 711  
 Myleran, 726  
 Mylotarg, 726  
 myocardial infarction, treatment of, 624  
 Myotonine, 726  
 myrrh, 413
- N**
- nabiximols, 2, 720  
 NAD<sup>+</sup>, 30, 35–6, 162  
 NADH, 30, 35–6, 232  
 nadolol, 624, 720, 738  
 NADP<sup>+</sup>, 35, 38, 179  
 NADPH, 35  
   cofactor for aromatase, 539  
   cofactor for dihydrofolate reductase, 419  
   cofactor for HMG-CoA reductase,  
   178–80  
   cytochrome P450 oxidation, 94, 158  
   nitric acid synthesis, 38  
 nafcillin, 431–2  
 nalbuphine, 649  
 nalfurafine, 655–7, 720, 738  
 nalidixic acid, 414, 458–9, 720, 738  
 nalmefene, 639, 720, 738  
 Nalorex, 726  
 nalorphine, 638, 640, 647, 649  
 naloxone, 638, 640, 649, 720, 738  
 naltrexone, 174, 629, 638–40, 649, 651, 717,  
   720, 738  
   dimer, 655  
 naltrindole, 651  
 nanospheres, 520  
 nanotubes, 268  
 Narcan, 726  
 Nardil, 726  
 narlaprevir, 509  
 Nasacort, 726  
 nasal congestion, treatment of, 618  
 nasal decongestants, 169, 611, 617  
 Nasofan, 726  
 Nasonex, 726  
 nasopharyngeal carcinoma, 514  
 Natalizumab, 268, 720  
 National Institute for Health and Clinical  
   Excellence, 285  
 natural products, 289  
   as a source of lead compounds, 199–202  
   in cancer treatment, 566–7  
 nausea, suppression of, 206  
 Navelbine, 726  
 Nebcin, 726  
 neck cancers, treatment of, 530, 534, 569, 574  
 neem tree, 687  
 Negaban, 726  
 Negram, 726  
 neighbouring group effect, 124  
 neighbouring group participation, 430,  
   584–5  
*Neisseria gonorrhoeae*, treatment of, 442  
*Neisseria meningitidis*, treatment of, 443  
 nelarabine, 533–4  
 nelfinavir, 478, 481, 490–1, 493–4, 720, 738  
 neomycin, 451–2, 717, 720, 738  
 neomycin sulphate, 717–20  
 neoplasm, 514  
 Neoral, 726  
 neostigmine, 599–600  
 nephron, 168  
 Nerisone, 726  
 nerve action, 711–14  
 nerve agents, 600–1  
   protective agent, 600  
 Neu5Ac2en, *see* 2-deoxy-2,3-dehydro-  
   N-acetylneuraminic acid  
 Neulasta, 726  
 Neupogen, 726  
 neuraminidase, 469, 496–501, 503, 505  
   inhibitors, 498–9, 501–6  
 neurodegenerative disease, treatment  
   of, 190  
 neuroleptic agents, 205, 208  
 neuromuscular blockers, 115, 591–4  
   reversal of action, 600  
 neuromuscular endplate, 711  
 neuron, 42, 578, 711  
 Neurontin, 726  
 neuropeptides, 580, 700  
 neurotransmission, adrenergic system,  
   612–13  
 neurotransmitters, 42, 44, 578  
   as drugs, 265–6  
 neutrophils, 27, 137  
 nevirapine, 234, 478–81, 720, 738  
 new chemical entity, 283, 284  
 New Drug Application, 283  
 new molecular entity, 283  
 Nexavar, 726  
 Nexium, 684, 726  
 Nicorette, 726  
 nicotinamide adenine dinucleotide,  
   *see* NAD<sup>+</sup>  
 nicotine, 1–2, 42, 720, 738  
   ability to cross placental barrier, 157  
   administration, 169–70  
   cholinergic agonist, 582  
   excretion, 167  
   source, 199, 582  
   structure, 582  
 nicotine patches, 169  
 Nicotinell, 726  
 nicotinic agonists, 115, 586–7  
 nicotinic antagonists, 115, 590–4  
 nicotinic receptor, 52, 594–5  
   binding site, 582–5  
   in the peripheral nervous system, 579  
   location, 582, 590  
   regulation of, 56, 106  
   structure, 48, 591, 595  
   subtypes, 115, 582  
   types, 115  
 nifedipine, formulation, 173  
 nifedipine hydroxylase, 682  
 nigericin, 147  
 nilotinib, 285, 554–5, 559, 720, 738  
 Nipent, 726  
 NiQuitin CQ, 726  
 nitric oxide, 38, 191, 207, 580–1  
 nitric oxide synthase, 38, 191  
*ortho*-nitrobenzylcarbamate protecting  
   group, 464–5

nitrofurantoin, 128, 460–2, 720, 738  
 nitrogen mustards, 124, 526–8  
 nitroimidazoles, 128, 460, 462, 685  
 nitroreductase, 571, 573  
 nitrosoureas, 124, 126  
 nitroveratryloxycarbonyl, 331–2  
 Nivaquine, 726  
 nizatidine, 677–9, 720, 738  
 NO synthase, *see* nitric acid synthase  
 Nobel Prize, 622  
 nocardicins, 444  
 nociceptin, 636, 650  
 Nolvadex, 726  
 non-competitive inhibitor, 90  
 non-nucleoside reverse transcriptase inhibitors, 479–81  
 non-steroidal anti-inflammatory drugs, 233–4, 659  
 non-structural protein 5A, inhibition of, 509  
 noradrenaline, 578, 609, *see also*  
 adrenergic receptors, adrenergic agonists, adrenergic antagonists, false transmitters, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors  
 as a lead compound, 204, 253  
 binding site interactions, 614–16  
 biosynthesis, 611–12  
 in the peripheral nervous system, 43, 579, 609  
 metabolism, 95, 612  
 neurotransmission process, 612–14  
 overlay with desipramine, 627–8  
 presynaptic control systems, 580–1, 613  
 release from storage vesicles, 627  
 reuptake inhibition, 135, 189, 594, 627–9, 701  
 role in depression, 700  
 structure, 42, 44, 235, 253, 581, 611  
 noradrenaline reuptake inhibitors, 629, *see also* selective noradrenaline reuptake inhibitors  
 norbinaltorphimine, 655–6  
 Norcuron, 726  
 nordazepam, 260–1  
 norepinephrine, 609, *see* noradrenaline  
 normorphine, 637–9  
 Norvir, 726  
 Novantrone, 726  
 novocaine, 237  
 NS5B RNA-dependent RNA polymerase, 509  
 inhibition of, 509  
 nuclear hormone receptors, 55  
 nuclear magnetic resonance spectroscopy  
 active conformations, 227–8, 673  
 enzyme mechanistic studies, 501  
 in drug design, 243  
 in lead discovery, 209–10  
 metabolite identification, 276  
 monitoring reactions, 324  
 predicted chemical shifts, 338  
 screening for lead compounds, 197  
 structure determination, 26, 212, 289, 329

nuclear transcription factors, *see*  
 transcription factors  
 nucleases, 271  
 nucleic acid bases, 72  
 nucleic acids as drug targets, 524–31  
 nucleocapsids, 469–70  
 nucleoside reverse transcriptase inhibitors, 478–9, 481  
 nucleosides, 71  
 nucleosome, 76, 519, 564  
 nucleus, 4  
 Nuclin, 726  
 nutlins, 142  
 Nuvigil, 726  
 Nystaform-HC, 726  
 nystatin, 718–19

## O

obesity, *see* antiobesity agents  
 oblimersen, 271, 529, 720  
 ocl144-093, 523  
 octreotide, 540  
 ofatumumab, 569, 720  
 ofloxacin, 459, 720, 738  
 olanzapine, 114, 116, 194, 720, 738  
 olefin metathesis, 334  
 oligonucleotides, 175, 315  
 as drugs, 174, 271–2, 493–4, 529  
 molecular tags in combinatorial synthesis, 329–30  
 protein interactions, 143  
 olivanic acids, 445  
 omalizumab, 267, 720  
 omeprazole, 96, 659, 680–6, 720, 738  
 ON-012380, 555  
 Onbrez, 726  
 Oncaspar, 726  
 oncogenes, 514  
 Oncovin, 726  
 ondansetron, 192, 206, 530, 720, 738  
 Onkotrone, 726  
 Operation Desert Shield, 600  
 ophthalmic examinations, 588–9  
 ophthalmology, use of glucocorticoids, 696–9  
 opioid dependence maintenance therapy, 644  
 opioid receptors, 62, 115, 206, 635–6  
 opioids, 632–57  
 peripheral acting, 655  
 $\delta$ -selective, 650–1  
 opium, 632  
 opium poppy, 202  
 opportunistic pathogen, 426  
 oral infections, 435  
 treatment of, 423, 457, 462  
 Oramorph, 726  
 organoarsenicals, 465  
 organophosphates, 96, 601, 600–3  
 antidote, 602, 603  
 Orimeten, 726  
 oripavines, 644–6  
 pharmacophores, 228  
 ORL1-receptor, 650  
 orlistat, 89–90, 200

orphan drugs, 284, 566  
 orphan receptors, 191, 206, 636  
 orphanin-FQ, 650  
 ortataxel, 138  
 orvinols, 644–7  
 oseltamivir, 284, 503, 505, 720, 738  
 osteoporosis, treatment of, 266, 268, 540  
 otitis media, treatment of, 423  
 Otomize, 726  
 Otosporin, 452, 726  
 ovarian cancer, treatment of, 527, 530, 543  
 overlays, 351–2  
 acetylcholine and atropine, 588  
 cocaine and procaine, 351–2  
 desipramine and noradrenaline, 628  
 oxaburimamide, 669–70  
 oxacillin, 252, 432  
 oxalic acid, 88  
 oxaliplatin, 529–30, 720, 738  
 oxamniquine, 250, 261, 263, 276, 305, 308–10, 720, 738  
 synthesis, 310  
 oxazolidinones, 452, 456–7  
 Oxecta, 174, 726  
 oxidoreductases, 36  
 oximinocephalosporins, 440  
 oxmetidine, 674–5  
 6-oxomorphine, 633–4  
 oxotremorine, 586–7  
 oxprenolol, 624, 720, 738  
 oxycodone, 720, 738  
 formulation, 174  
 oxymetazoline, 618  
 oxymorphone, 639  
 oxymorphone, 655  
 oxytetracycline, 454, 718  
 oxytocin, 23, 720

## P

p15 protein, 517  
 p16 protein, 517  
 p21 protein, 517  
 p27 protein, 517  
 p53 protein, 142, 515, 517–19, 573  
 paclitaxel, 12, 137–8, 199–200, 211, 542, 720, 739  
 clinical aspects, 534, 543, 569  
 synthesis of, 289  
 paediatric use marketing authorisation (PUMA), 281  
 pain, treatment of, 611, *see also* analgesics  
 palinavir, 490–1  
 palivizumab, 511, 720  
 Palladia, 726  
 Palladone, 726  
 pamaquine, 299  
 Pamergan P100, 726  
 pan-class resistance mutation, 479  
 pancratistatin, 566  
*Pancreatium littoralis*, 566  
 pancreas, 171  
 pancreatic cancers, 544  
 treatment of, 530, 534



- pancreatic lipase, 35, 90, 200  
 pancuronium, 592–3  
 pandemic, 496  
 panic attacks, 237  
 panitumumab, 280, 569, 720  
 pantoprazole, 96, 680–2, 685, 720, 739  
*Papaver somniferum*, 632  
 papillomaviruses, 474, 514  
 paracetamol, 163, 277  
 parallel synthesis, 313, 322–7, 557  
 Paraplatin, 726  
 parasympathetic nerves, 579  
 parathion, 601–2  
 pargyline, 261  
 Pariet, 726  
 parietal cells, 659–60, 679–80  
 Parkinson's disease, 192  
   treatment of, 95–6, 115, 260, 588  
 paroxetine, 136, 720, 739  
 partial agonists, 111–13, 624  
 partial charges, 341–2  
 partial least squares, 402  
 partition coefficients, 248, 385–8  
 Pasteur, Louis, 413, 421  
 patent cliff, 282  
 Patent Cooperation Treaty, 281  
 patents, 281–3  
 pathological chaperone, 605  
 pay-for-delay deals, 282  
 pazopanib, 558–60, 720, 739  
 PDGF, *see* platelet-derived growth factor  
 PDGF-R, *see* platelet-derived growth factor  
   receptor  
 peanuts, 3  
 Pearl Harbor, 1  
 PEG, *see* polyethylene glycol  
 pegademase, 267, 720  
 pegaptanib, 143, 174, 720  
 pegaspargase, 267, 720  
 Pegasys, 726  
 pegfilgrastim, 267, 720  
 peginterferons, 267, 720  
 Peg-Intron, 726  
 pegvisomant, 267, 720  
 pegylated alpha interferon, 508  
 pelvic inflammatory disease, treatment  
   of, 462  
 pemetrexed, 532–3, 720, 739  
 Penbritin, 726  
 penciclovir, 261, 473–5, 720, 739  
 penicillanic acid sulphones, 445  
 penicillin acylase, 429  
 penicillin binding protein, 428  
 penicillin G, 422, *see* benzylpenicillin  
 penicillin G acylase, 570  
 penicillin methyl ester prodrugs, 196  
 penicillin N, 433  
 penicillin T, 433  
 penicillin V, *see* phenoxymethylpenicillin  
 penicillinases, 428  
 penicillin-resistant gonococci, 462  
 penicillin-resistant meningococci, 462  
 penicillins, 1–2, 12, 421–36  
   administration, 153  
   bactericidal agent, 418  
   carbonyl stretching frequency, 344  
   in the synthesis of cephalosporins, 439  
   passage through the blood–brain  
   barrier, 157  
   role in fungal survival, 94  
*Penicillium chrysogenum*, 428  
*Penicillium citrinum*, 180  
 pentagastrin, 671–2  
 pentazocine, 641, 649, 720, 739  
 pentobarbital, 173  
 pentostatin, 96, 534–5, 720, 739  
 Pepcid, 677, 726  
 pepsin, 686  
 peptic ulcers, 659  
 peptidases, 160, 163, 165, 486, 537, 562,  
   570, 650–1, *see also* aminopeptidase,  
   carboxypeptidase, dihydropeptidase,  
   methionine aminopeptidase, and  
   transpeptidase  
   inhibitors, 653  
 peptide antibiotics, 414  
 peptide bonds, 17–18, 23  
   hydrolysis, 34  
   isostere, 545–6  
 peptide drugs, 266–7, 270  
 peptide synthesis, 314, 316  
 peptidoglycan structure, 423  
 peptidomimetics, 268–70  
 peptoids, 317  
 peramivir, 506, 720, 739  
 perfused liver systems, 277  
 peripheral nervous system, 578–80, 609  
 periplasmic space, 415  
 peritonitis, treatment of, 442, 451  
 permetrexed, 96, 532  
 personalized medicine, 76, 166, 280, 522  
 pesticides, 2  
 pethidine, 172, 642, 649, 720, 739  
   pharmacophores, 228  
 petopenem, 443  
 petoprolol, 626  
 Pfizer pharmaceuticals, 305, 308  
 P-glycoprotein, 138, 523, 525, 527, 542–3  
 PHA-665752, 242  
 phage, 82  
 pharmaceutical phase, 153, 173  
 Pharmacia Biosensor, 197  
 pharmacodynamic phase, 153  
 pharmacodynamics, 5, 105, 215  
 pharmacogenomics, 166  
 pharmacogenosy, 199  
 pharmacokinetic phase, 153  
 pharmacokinetics, 11, 105, 153, 248  
 pharmacology testing, 277  
 pharmacophore triangles, 227, 355–6, 362,  
   364, 379  
 pharmacophores, 105, 209, 227–8, 354–6  
   acetylcholine, 584–5  
   analgesic, 635  
   artemisinin, 301  
   colchicine, 405  
   dopamine, 355–6  
   in screening for lead compounds, 366  
   local anaesthetics, 237, 351  
   mitoxantrone, 525  
   muscarinic receptor, 586  
   role in docking programs, 362–4  
   taxoids, 542  
   tipranavir, 492  
   tubocurarine, 353  
   use in aligning molecules, 368, 401, 403  
   use in planning combinatorial  
   syntheses, 379  
 Pharmorubicin, 726  
 phase I drug metabolism, 158  
 phase II drug metabolism, 158  
 phase separation columns, 324  
 phenazocine, 641  
 phenelzine, 96, 172, 629–30, 720, 739  
 Phenergan, 726  
*N*-phenethyllevorphanol, 641  
*N*-phenethylmorphine, 639, 647–8  
 phenobarbital, 166–7  
 phenobarbitone, *see* phenobarbital  
 phenols, binding role, 216–17  
 phenoxymethylpenicillin, 422–3, 428–31,  
   463, 720, 739  
 phenprocoumon, 492–3  
 phentermine, 616, 629, 720–1, 739  
 phenylalanine, 17, 22, 705  
   adrenergic receptor binding site,  
   614–15  
   angiotensins, 296  
   catacholamine binding site, 368  
   endogenous opioids, 645, 649–50, 653  
   farnesyl transferase inhibitors, 545  
   HIV-protease inhibitors, 484  
   HIV-protease mutation, 489  
   HIV-protease substrates, 482, 484  
   human rhinovirus, 508  
   in alkylating agents, 528  
   rigidification, 239  
   transport protein, 155  
 phenylalanine hydroxylase, 80  
*L*-phenylalanine mustard, 527  
 phenylbutazone, 279–80  
 phenylketonuria, 80  
 phenylpiperidine analgesics, 642–3  
 Philadelphia chromosome, 559  
 phosphatase, 61–2, 66  
 phosphatidylcholine, 3, 175  
 phosphatidylethanolamine, 3  
 phosphatidylinositol, 3, 65  
 phosphatidylinositol diphosphate, 64–6  
 phosphatidylserine, 3  
 3'-phosphoadenosine 5'-phosphosulfate,  
   162, 165  
 phosphodiesterase enzyme, 96  
 phosphoglyceride, 3–4  
 phospholipase C, 59–60, 64–5, 67  
 phospholipids, 3–4  
 phosphoramidase, 528  
 phosphorylase a, 61  
 phosphorylase b, 38, 61  
 phosphorylase kinase, 61–2  
 phosphorylases, 36–8, 61–2  
   inhibitor, 62

- phosphorylation, 25, 63–4, *see also* protein kinases, cyclin-dependent kinases, kinase-linked receptors, serine-threonine kinases, tyrosine kinases, MAP-kinase, and thymidine kinase  
activation of antiviral agents, 473–4, 478, 510  
activation of kinases, 549  
desensitization, 114  
drug resistance, 453, 464–5
- photodynamic therapy, 264, 521, 573–4  
photolithography, 331–2  
photosensitivity, 574  
photosensitizing agents, 264, 573  
phyllanthoside, 540–1  
physical dependence, 173  
*Physostigma venenosum*, 598  
physostigmine, 96, 598–9, 603  
PI synthase, 66  
PI-4-kinase, 66  
PI-4-P5-kinase, 66  
pi-cation interaction, 9, 221  
picoprazole, 683  
picornaviruses, 507  
Picovir, 726  
pilocarpine, 586–7, 720, 739  
Pilogel, 726  
pindolol, 623–5  
pinocytosis, 155  
PIP<sub>2</sub>, *see* phosphatidylinositol diphosphate  
piperacillin, 435, 445, 720, 739  
pirenzepine, 589–90  
pitavastatin, 182  
Pitressin, 726  
pivampicillin, 434  
PKA, *see* protein kinase A  
PKC, *see* protein kinase C  
PKI-166, 551  
placebo, 202, 278–9  
placental barrier, 157  
plasmids, 82, 175, 428, 463  
*Plasmodium falciparum*, 299  
Plasmodium genus, 299  
plasmons, 198  
platelet aggregation inhibitor, 240  
platelet-derived growth factor, 515, 554  
platelet-derived growth factor receptor, 554–5  
inhibition of, 552  
platinum drugs, 125–7, 529–30, 533  
β-pleated sheet, 18–19  
pleconaril, 507–8, 720, 739  
plums, 3  
pneumonia, 414  
in AIDS patients, 470  
treatment of, 435, 443, 453, 457, 459  
pocket factor, 507  
podophyllotoxins, 122, 128, 474–5, 526, 540–1, 543, 720, 739  
podophyllum, 540, 543  
*Podophyllum emodi*, 540  
*Podophyllum peltatum*, 540  
polar surface area, 155  
polio, 468, 507  
treatment of, 470
- poly ADP ribose polymerase, inhibitors of, 536  
polyamides, 131  
polyamines, 244  
polyethylene glycol, 143, 174–5, 267–8, 315  
Polyfax, 726  
polyglutamate, 174  
polyglutamylation, 531  
polymeric micelles, 574  
polymyxin B, 147, 450–2, 720, 739  
polymyxin B sulphate, 718–19  
polypharmacology, 560, 564  
porins, 427, 433, 443, 454, 459, *see also* aquaporins  
porphyrins, 264, 521, 573–4  
Porton Down, 600–1  
Posiject, 726  
post-translational modifications, 25–6  
posttraumatic stress disorder, treatment of, 624  
potassium ion channels, 59, 192  
potency, 116, 118  
PPBI, *see* protein–protein binding inhibitor  
PPI, *see* proton pump inhibitor  
practolol, 207–8, 279, 623, 625–6  
pralatrexate, 96, 532–3, 720, 739  
pralidoxime, 602–3  
Pravachol, 726  
pravastatin, 181, 720, 739  
praziquantel, 309–10, 720, 739  
prazosin, 620–1, 720, 739  
pRB protein, 517  
Pred Forte, 726  
prednisolone, 537, 540, 690–3, 739  
prednisolone acetate, 693, 696, 720, 739  
prednisolone hexanoate, 693  
prednisolone metasulphobenzoate, 693  
prednisolone sodium phosphate, 693, 696, 720, 739  
prednisone, 537, 690–1  
Predsol, 726  
Predsol-N, 726  
pregnane, 690  
premature labour, delay of, 618  
prenylations, 546  
presynaptic receptors, 580, 581, 613–14, 621, *see also* autoreceptors  
Prexige, 726  
Prezita, 726  
Priadel, 726  
Prilosec, 726  
primaquine, 299  
Primaxin, 726  
principle of chemotherapy, 413  
Prinivil, 726  
prinomastat, 562, 563  
Prioderm, 726  
pristinamycin, 456, 457  
privileged scaffolds, 319  
PRO-3112, 250  
Pro-Banthine, 726  
probe atoms, 344–5, 364, 407  
Probecid, 726
- probenecid, 265, 436, 475, 720, 739  
procaine, 237, 252, 265, 351–2  
procarbazine, 126–7, 530  
procaspase 9, 518  
process development, 286, 289  
Prodock, 366  
prodrugs, 124, 222, 258–64  
aciclovir, 472  
activated by HIV protease, 493  
artemisinin, 302  
carbenicillin, 435  
famciclovir, 473  
for aciclovir, 473  
for ampicillin, 434  
for amprenavir, 491  
for dopamine, 260  
for NRTIs, 479  
for penicillin G, 434  
oseltamivir, 505  
oxamniquine, 309  
prontosil, 416  
succinyl sulphathiazole, 418  
sulphonamides, 416  
prodynorphin, 650  
proenkephalin, 650  
proflavine, 120–1, 414, 459  
progestins, 537, 540  
prokaryotic cells, 415  
PRO-LEADS, 366  
Proleukin, 726  
Prolia, 726  
proline, 705  
promethazine, 205, 720, 739  
promiscuous inhibitors, 196  
promiscuous ligands, 194, 244, 606  
pronethalol, 206, 234–5, 622  
pronociceptin/orphanin FQ, 650  
prontosil, 414, 416  
pro-opiomelanocortin, 650  
ProPAM, 603  
propantheline, 739  
propantheline bromide, 589, 590, 720  
property-based drug design, 226  
prophylactics, 299  
cefazolin, 442  
cefotaxime, 442  
ceftriaxone, 442  
cefuroxime, 442  
ertapenem, 443  
for anthrax, 454  
for cancer, 521  
imipenem, 443  
methenamine, 462  
teicoplanin, 451  
propionaldehyde, 261  
propranolol, 207–8, 225–6, 243, 622–4, 720, 739  
prostaglandin receptors, 51, 613  
prostaglandins  
biosynthesis, 93, 222, 659  
chemical messengers, 44  
enhanced synthesis, 686  
in presynaptic control, 613  
prostate cancer, 522  
treatment of, 530, 538, 540, 566

- prostatic hyperplasia, treatment of, 611  
 prosthetic groups, 35  
 proteases, 265, *see also* ACE, caspases, cathepsin D, HIV protease, renin, serine proteases, and transpeptidases inhibitors, 260, 265  
 proteasome, 96, 563 inhibitors, 563  
 protein kinase A, 59–62  
 protein kinase C, 59, 65, 67, 272, 529, 553 inhibition, 525  
 protein kinases, 37–8, 547–8 inhibitors, 559, 547–60 type I inhibitors, 549 type II inhibitors, 549 type III inhibitors, 549  
 protein mapping, 366–9  
 protein therapy, 566  
 protein–protein binding inhibitors, 135, 139–43, 266, 493, 495  
 protein–protein interactions, 28, 39  
 proteins as drugs, 266–67  
 proteoglycans, 148, *see* glycoproteins  
 proteomics, 26, 191  
 Protium, 726  
 protomers, 469  
 proton pump, 96, 660, 679–80 inhibitors, 263, 659–60, 679–85  
 proto-oncogenes, 514  
 protozoa, 716  
 Provera, 726  
 Provigil, 726  
 proviral DNA, 477  
 provirus, 477  
 Prozac, 136, 189, 726  
 pseudoatom, 359, 360  
 pseudoephedrine, 617, 720, 739  
*Pseudomonas aeruginosa*, 425–6, 435, 570, 715 treatment of, 426, 435, 442–3, 451, 453, 459  
*Pseudomonas fluorescens*, 464  
 pseudoreceptors, 368, 404  
 PS-isocyanate, 324, 325  
 PS-trisamine, 324, 325  
 puffer fish, 202  
 Pulmicort, 726  
 purgative, 202  
 purine, 72  
 purine antagonists, 536  
 Puri-Nethol, 726  
 puromycin, 139  
 pyelonephritis, treatment of, 453  
 pyrazinamide, 460–1  
 pyridostigmine, 599–600, 721, 739  
 pyridoxal phosphate, 35  
 pyrimethamine, 418, 721, 739  
 pyrimidine, 72  
 Pyrogastrone, 726  
 pyrrole ring, bioisostere for amide, 235  
 pyruvic acid, 30, 32, 35–6, 39
- Q**
- qinghao, 299  
 qinghaosu, 299
- Qnexa, 726  
 quantitative structure activity relationships (QSAR), 383–9, 391–9, 401, 403–5, 676 statistics, 707–10 3D QSAR, 401–5  
 quantum mechanics, 337  
 Quasar, 404  
 quaternary ammonium ion, binding role, 221  
 Queen's Award for Technological Achievement, 308  
 Quellada M, 727  
 Questran, 727  
 quinine, 199, 202, 211, 299, 523, 739  
 quinolone antibacterial agents, 123, 414, 457–9  
 quinupristin, 456–7, 721, 739  
 Qvar, 727
- R**
- Rab protein, 67  
 rabeprazole, 96, 680–1, 685, 721, 739  
 rabies, 468  
 racecadotril, 96, 653–4, 721, 739  
 racemase, 423  
 racemate, 104  
 Radezolid, 457  
 radioimmunotherapy, 569  
 radioligand labelling, 116  
 radioligand studies, 195  
 radiotherapy, 514, 521, 569  
 radishes, 3  
 Raf protein, 67–8, 272, 529  
 Raf-1 kinase, 557  
 raloxifene, 109–10, 538, 540, 721, 740  
 raltegravir, 495, 721, 739  
 raltitrexed, 531, 533, 534, 721, 739  
 Ran protein, 67  
 ranibizumab, 268, 721  
 ranitidine, 659, 676–7, 679, 721, 740  
 rapamycin, 560  
 Raplacta, 727  
*ras* gene, 514, 544  
 Ras protein, 67–8, 514–16, 544–6 inhibition, 544  
 rasagiline, 244  
 rasfonin, 200–1  
 rashes, treatment of, 661  
 Rebetol, 727  
 reboxetine, 628–9, 721, 740  
 receptor dimers and dimerization, 53–5 opioid, 654–5  
 receptor mediated endocytosis, 496  
 receptors, *see also* the following receptors (adrenergic,  $\gamma$ -aminobutyric acid, angiotensin, autoreceptors, calcium sensing, cannabinoid, CD20, chemokine, c-kit, catecholamine, cholinergic, cytokine, dihydropyridine, dopamine, epidermal growth factor, ERB B2, estrogen, fibroblast growth factor, gastrin, glutamate, glycine, growth hormone, HER2 growth factor, histamine, insulin growth factor, insulin, intracellular, kinase linked, low density lipoprotein, melanin-concentrating hormone, Met, muscarinic, nicotinic, nuclear hormone, opioid, ORL1, orphan, platelet derived growth factor, presynaptic, prostaglandin, G-protein coupled, rhodopsin, serotonin, transforming growth factor, tumour necrosis factor, tyrosine kinase, vascular endothelial growth factor, vasopressin) metabotropic glutamate like and pheromone, 52 rhodopsin like, 51–2 secretin-like, 52 types and subtypes, 52–3, 114  
 recombinant DNA technology, 81–2, 266  
 recommended international non-proprietary name, 12  
 reduced folate carrier, 533  
 reductases, 36, 158, 160, 163, *see also* aromatase, dihydrofolate reductase, HMG-CoA reductase, nitroreductase, ribonucleotide reductase.  
 Regorafenib, 558  
 regression coefficient, 384  
 regulatory affairs, 283–5  
 Relenza, 501, 727  
 Remicade, 727  
 remifentanyl, 643  
 Reminyl, 727  
 Remitch, 727  
 removal or replacement of susceptible metabolic groups, 253  
 renal artery, 168  
 renal cell carcinoma, treatment of, 559–60  
 renin, 91, 292, 483, 624 inhibitors, 90–2, 268, 483  
 renin inhibitors, 292  
 ReoPro, 727  
 replacing metabolically labile groups, 253  
 replication, 72–3 viruses, 469  
 Rescriptor, 727  
 reserpine, 202, 627, 700  
 resistance  
 aciclovir, 475  
 aminoglycosides, 453  
 antibacterial agents, 464  
 anticancer drugs, 523  
 anti-influenza drugs, 506  
 cephalosporins, 441  
 chloramphenicol, 454  
 fluoroquinolones, 459  
 macrolides, 457  
 NNRTIs, 481  
 penicillins, 425–8  
 ritonavir, 489  
 sulphonamides, 420  
 tetracyclines, 454–5  
 to NNRTIs, 479  
 trimethoprim, 420, 462  
 vancomycin, 447  
 reslizumab, 268  
 resonance-assisted hydrogen bonding, 225

- respiratory infections, 413  
 treatment of, 432, 442, 454, 457, 459
- respiratory syncytial infection, treatment of, 510–11
- Respontin, 727
- resting potential, 712
- restraining proteins, 517
- restriction enzymes, 81, 82
- restriction point, 516
- reticuloendothelial system, 175, 267, 574
- retinal, 367
- retinal inflammation, treatment of, 475
- retinoids, 55
- Retrovir, 727
- retroviral reverse transcriptase, 191
- retroviruses, 476, 573
- reuptake inhibitors, *see* noradrenaline  
 reuptake inhibition, serotonin reuptake inhibitors, selective serotonin reuptake inhibitors, anti-obesity drugs, dopamine reuptake inhibitors, dual reuptake inhibitors
- reverse transcriptase, 476–7  
 inhibitors, 478, 480–1, 493
- reversible enzyme inhibitors, 87–9
- Revex, 727
- Revlimid, 565–6, 727
- Reyataz, 727
- rhabdomyolysis, 181
- rheumatic fever, treatment of, 423
- rheumatoid arthritis, 266  
 treatment of, 93, 266, 268, 279
- Rhinocort Aqua, 727
- rhinovirus, 507
- Rho protein, 67
- rhodopsin, 51–2, 367
- rhodopsin receptor, 52
- rhubarb, 202
- riamcinolone acetone, 692
- ribavirin, 508, 510–11, 721, 740
- ribonucleic acid, 76–80, *see also*  
 messenger RNA, ribosomal RNA and transfer RNA  
 as a drug target, 131–3
- ribonucleotide reductase, 96, 534–5  
 inhibitors, 534
- ribose, 76, 148
- ribosomal RNA, 76–7, 79
- ribosomes, 77–8, 80, 452, 454
- ribozymes, 511
- ricin, 257, 570
- rickettsia, treatment of, 454
- rifabutin, 481
- Rifadin, 727
- rifampicin, 453, 460, 462, 721, 740
- rifampin, 481
- rifamycins, 200, 460, 462
- Rifater, 727
- Rifaximin, 460, 721, 740
- Rifinah, 727
- rigidification, 239–41  
 opioids, 644–7  
 oxamniquine, 306–7  
 serotonin antagonists, 702
- rilpivirine, 479–81, 721, 740
- Rimacid, 727
- Rimactane, 727
- Rimactazid, 727
- rimantadine, 498, 510
- rimexolone, 692, 696, 721, 740
- ring cleavage, 242
- ring contraction, 231  
 serotonin antagonists, 702
- ring expansion, 231, 233
- ring fusion, 234, 242
- ring variation, 233, 254–5  
 serotonin antagonists, 703
- Rink resin, 315–17
- RISC, *see* RNA induced silencing complex
- Risperdal, 727
- risperidone, 114, 116, 721, 740
- Ritalin, 629, 727
- ritonavir, 12, 264, 478, 485–9, 493–4, 721, 740
- Rituxan, 727
- rituximab, 569, 721
- rivastigmine, 244, 603–4, 721, 740
- RNA, *see* ribonucleic acid
- RNA induced silencing complex, 132–3
- RNA polymerase, 469, 496–7
- RNA-dependent RNA polymerase, 469
- Robinson, Sir Robert, 633
- Rocephin, 727
- Roche pharmaceuticals, 12, 484, 505
- rocuronium, 150, 592–3, 721, 740
- rofecoxib, 93, 95, 279, 721, 740
- Roferon-A, 727
- rohitukine, 556
- romidepsin, 564, 721, 740
- root mean square distance, 351
- roscovitine, 556
- rosuvastatin, 154, 181–4, 721, 740
- Rous sarcoma virus, 514
- Royal Navy, 632
- rubella, 468
- Rubex, 727
- rubidomycin, 524
- Russian flu, 496
- ruxolitinib, 556–7, 560, 721, 740

## S

- safety-catch acid-labile linker, 329–30
- Salamol Easi-Breathe, 727
- salbutamol, 170, 205, 253–4, 619–20, 721, 740
- salicin, 202
- salicylic acid, 222, 261, 285–6, 717
- salmefamol, 620
- salmeterol, 620, 719, 721, 740
- Salmonella typhimurium*, 194
- salt bridge, 21
- salvarsan, 414, 465
- Sandimmun, 727
- saquinavir, 12, 269, 484–6, 491, 721, 740  
 as a lead compound, 489–92  
 clinical aspects, 478, 481, 493
- SAR, *see* structure activity relationships
- sarcodictyins, 542–3
- sarin, 600–1
- Sativex, 727
- SB-213698, 652
- SB-269652, 258
- SB-269970, 703
- SB-656104, 704
- SB-269970, 703–4
- SC-57666, 234
- SC-58125, 234
- scabies, treatment of, 602
- scaffolds, 318–20, 333–4
- Scatchard equation, 117
- Scatchard plot, 117
- scavenger resins, 323–4
- Sch-226374, 546, 548
- Schild analysis, 118
- Schild plot, 118
- Schistosoma haematobium*, 305
- Schistosoma japonicum*, 305
- Schistosoma mansoni*, 305, 308
- schistosomes, 305
- schistosomiasis, 305, 310
- schizophrenia, treatment of, 194, 208
- SCID syndrome, treatment of, 267
- scintillation proximity assay, 198
- Scopoderm TTS, 727
- scopolamine, 588–9
- screening by NMR, 197
- search and destroy drugs, 256–7
- secondary messenger, 60
- secondary metabolites, 199
- $\beta$ -secretase, 257
- Sectral, 727
- Securon, 727
- sedation, 115
- sedatives, 260, 632, 644
- selective noradrenaline reuptake inhibitors, 628, 701
- selective optimization of side activities, 203, 205
- selective serotonin reuptake inhibitors, 136, 189–90, 630, 700, 701
- selective toxicity, 3, 414
- selegiline, 95, 96, 721, 740
- SELEX, 143
- self destruct mechanism, 465
- self-assembly, 469
- self-destruct drugs, 255
- self-regulation, 612
- seliciclib, 549, 556
- Selincro, 727
- semi-empirical quantum mechanics, 337–8
- semi-synthetic preparations, 289  
 artemisinin analogues, 300  
 paclitaxel, 289  
 penicillins, 428
- sensitization, 112, 114
- sentry drugs, 264–5
- sepsis, treatment of, 453
- septicaemia, 414  
 treatment of, 432, 443, 453, 459
- Seprin, 727
- sequential blocking, 420
- serendipity, 207
- Seretide, 727
- Serevent, 727
- serine, 17, 22, 705

- acetylcholinesterase active site, 597–9, 601–3  
acylation by  $\beta$ -lactam, 221  
acylation of, 90, 222  
adrenergic binding site, 614–15, 617  
alkylation, 89  
catalytic triad, 34–5, 90, 598  
catecholamine receptors, 368  
chymotrypsin, 34–5  
cyclooxygenase active site, 222  
HMG-CoA reductase, 179, 183  
 $\beta$ -lactamase active site, 427  
lipase active site, 90  
nucleophile, 34, 89, 92, 425, 508, 597  
phosphorylation, 25, 37, 60–1, 63–5  
Ras protein, 545  
transpeptidase active site, 221, 424–5, 437  
D-serine, 651  
serine proteases, 424–5, 508, 526  
serine-threonine kinases, 60, 63, 67, 548, 553, 556  
serotonin  
  as neurotransmitter, 42  
  in the enteric nervous system, 580  
  metabolism of, 95  
  presynaptic control, 621, 701  
  reuptake inhibitors, 135–6, 189–90, 628, 630, 700–1  
  role in depression, 621, 700  
  structure, 44  
  see also selective serotonin reuptake inhibitors  
serotonin agonists, 106, 115, 189, 205, 236  
serotonin antagonists, 115, 236, 344, 701–4  
  as antidepressants, 287, 701  
  as antiemetics, 192, 530  
  treatment of schizophrenia, 194  
serotonin receptors, 50–1  
  inherent activity, 112  
  model binding site, 369  
  targets for antidepressants, 701  
  types and subtypes, 115, 701  
Seroxat, 727  
sertraline, 136, 721, 740  
serum paraoxonase, 698, 699  
setrobutvir, 509, 510  
severe acute respiratory syndrome (SARS), 468  
severe combined immunodeficiency disease, 267  
Sevredol, 727  
Sheehan, John, 422, 428  
Sheppard's polyamide resin, 315  
Shingles, treatment of, 472, 475  
Shock, treatment of, 627  
siRNA—see small inhibitory RNA  
sialic acid, 496–7, 499–501, 506  
sialidase, 496–7  
sibutramine, 135–6  
signal proteins, 50, see also G-proteins and Ras  
signal transduction, 58–68  
sildenafil, 12, 96, 204, 208, 721, 740  
  to improve drug access to CNS, 157  
silibinin, 687  
silichristin, 687  
siliianin, 687  
silphion, 200  
silver sulphadiazine, 417  
*Silybum marianum*, 687  
silymarin, 687  
simplification, 181, 236–9, 640–4  
  anthracyclines, 524  
  artemisinin analogues, 302–4  
  CC 1065 analogues, 529  
  glycopeptides, 449–50  
  HIV-protease inhibitors, 491–2  
  muscarinic antagonists, 589  
  of lucaanthone, 305  
  opioids, 640–1, 643–4  
  serotonin antagonists, 702  
  statins, 181  
simulated annealing, 349, 366  
simvastatin, 96, 181, 184, 719, 721, 740  
Sinemet, 727  
singlet oxygen, 574  
sinusitis, treatment of, 435, 454, 457, 459  
sirolimus, 560  
SKF 91581, 667–8  
skin cancer, treatment of, 525, 533  
skin creams, fusidic acid, 462  
skin infections, treatment of, 442, 451–52, 457, 459, 464  
skin melanoma, see melanoma  
sleep medicines, 106  
sleeping agents, 573  
  drug design, 264  
  medicines, see sedatives and tranquilizers  
sleeping sickness, 191  
  treatment of, 414, 465  
Slo-Phyllin, 727  
small G-proteins, 67, 544  
small inhibitory RNAs, 132–3, 175  
small interfering RNAs, 132  
small nuclear RNAs, 79  
smallpox, 468, 511  
  treatment of, 470, 511  
smart drugs, 603–4  
Smith Kline and French, 660  
SmithKline Beecham, 701  
smoking  
  treatment, 587  
SN-38, 526  
snake toxins, 2, 201, 293, 594–5  
snakeroot plant, 202  
SNC-80, 652  
snowdrop bulbs, 603  
snRNA, see small nuclear RNA  
sodium artesunate, 300–1, 303  
sodium bicarbonate, 659  
sodium ion channel, 712  
sodium-2-mercaptoethane sulphonate, 528  
Sofradex, 727  
soft drugs, 167  
soft steroids, 695, 697–9  
soft tissue infections, treatment of, 457, 459  
soft tissue sarcomas, treatment of, 530  
Solanaceae plants, 202  
solid phase extraction, 323–4  
solid phase techniques, 314–21  
solid supported reagents, 324  
Solu-Cortef, 727  
Solu-Medrone, 727  
solution phase organic synthesis, 322  
soman, 600–1  
somatic gene therapy, 83  
somatic motor nervous system, 579  
somatostatin, 540  
Somavert, 727  
SOMFA, 404  
sorafenib, 243, 283, 285, 549, 557–9, 721, 740  
soterenol, 619  
soybean curd, 413  
Spanish flu virus, 496  
spinach, 3  
spindle, 27  
spiroalkyl trioxanes, 303  
spliceosome, 79  
splicing mRNA, 80  
spongistatin 1, 540–1  
SPROUT, 374–6  
Sprycel, 727  
SQ-13297, 294  
Src kinase, 555  
  inhibition of, 552  
St. John's wort, 167, 212  
stability tests, 277  
Stalevo, 727  
standard deviation, 384, 708  
standard error of estimate, 384  
*Staphylococcus aureus*, 413, 426–8, 463, 715  
  resistance, 462  
  treatment of, 431–2, 441–2, 451  
starch, 148  
statins, 178–84, 243  
  anticancer activity, 546  
  type I statins, 181  
  type II statins, 181–2  
staurosporine, 556  
stavudine, 478–9, 481, 721, 740  
steady state concentration, 172  
steric and electronic modifications, 252  
steric block, 217, 230  
steric blockers, 232  
steric factors, 390–1  
steric fields, 401–2  
steric shields, 105, 251, 252  
  cephalosporins, 438  
  in cholinergic agonists, 585  
  in farnesyl transferase inhibitors, 546, 548  
  in matrix metalloproteinase inhibitors, 562  
  in penicillins, 430–2, 434  
  in peptidomimetics, 269  
  vancomycin, 447  
sterilizing agent, 413  
Sterimol, 391  
steroids, 12, 55–6, 536, see also cholesterol,  
  fusidic acid, hormone-based therapies,  
  estradiol, estrone, glucocorticoids,  
  pancuronium, vecuronium  
  active conformation, 403  
  administration, 170  
  anti-inflammatory agents, 689–99  
  biosynthesis, 191  
  corticosteroid, 193



- steroids (*Continued*)  
 nomenclature, 689  
 scaffolds, 320  
 substrate for aromatase, 539
- stibocaptate, 305
- stomach cancer, 514  
 treatment of, 559
- storage vesicles, 627
- Stratter, 727
- Streptococcus pneumoniae*, 442  
 resistance, 462  
 treatment of, 457
- streptogramins, 456–7
- Streptomyces antibioticus*, 535
- Streptomyces aureofaciens*, 454
- Streptomyces caespitosus*, 127
- Streptomyces cattleya*, 442
- Streptomyces clavuligerus*, 439, 444
- Streptomyces erythreus*, 455
- Streptomyces garyphalus*, 445
- Streptomyces griseus*, 452
- Streptomyces hygrosopicus*, 560
- Streptomyces lincolnensis*, 456
- Streptomyces mediterranei*, 460
- Streptomyces nodosus*, 145
- Streptomyces olivaceus*, 445
- Streptomyces orientalis*, 446
- Streptomyces parvullis*, 121
- Streptomyces peucetius*, 121, 524
- Streptomyces pristinaespiralis*, 456
- Streptomyces roseosporus*, 451
- Streptomyces toxytricini*, 200
- Streptomyces venezuela*, 455
- Streptomyces verticillus*, 121, 525
- streptomycin, 414, 452, 453, 462
- streptomycin-resistant *E. coli*, 463
- streptozotocin, 124, 126, 530
- stress, treatment of, 624
- stroke, treatment of, 116, 190
- stromelysins, 561
- structural overlays, *see* overlays
- structural proteins, as drug targets, 138, 539, 541–3
- structure determination, 212
- structure–activity relationships, 215–27  
 Abelson tyrosine kinase inhibitors, 553  
 acetylcholine, 583  
 artemisinin, 300  
 aryloxypropanolamines, 622–3  
 atracurium, 593  
 atropine, 589  
 by NMR, 209  
 catecholamines, 615–16  
 cephalosporins, 437  
 clavulanic acid, 444  
 EGF receptor kinase inhibitors, 550  
 enkephalins, 650  
 famotidine, 678  
 farnesyl transferase inhibitors, 547  
 histamine, 662  
 histamine agonists, 662  
 in drug optimization, 226  
 mitoxantrone analogues, 524  
 morphinans, 640  
 morphine, 633–4  
 muscarinic antagonists, 589  
 neuraminidase inhibitors, 502  
 penicillins, 429  
 physostigmine, 598  
 Raf-1 kinase inhibitors, 557  
 ranitidine, 676  
 sarcodictyins, 542  
 serotonin analogues, 369  
 sulphonamides, 416
- structure-based drug design, 241–2, 407, 490, 508
- SU-11248, 549
- subcutaneous injection, 170
- suberoylanilide hydroxamic acid, 740, *see* vorinostat
- Sublimaze, 727
- substance P, 581, 700
- substituent hydrophobicity constants, 386–8
- substrate, 30
- Subutex, 727
- succinyl proline, 231, 293–5
- succinyl sulphathiazole, 418
- Sudafed, 617, 727
- sufentanil, 643
- Sugammadex, 150, 721, 740
- suicide substrates, 92–5, 445, 532–3, 539  
 clavulanic acid, 445
- sublactam, 445
- sublactam pivoxil, 445
- Suleo-M, 727
- sulmazole, 387
- sulpha drugs, 414, 416
- sulphadiazine, 417
- sulphadoxine, 418, 721, 740
- sulphamethoxazole, 420
- sulphanilamide, 205, 416
- sulphate conjugation, 162
- sulphathiazole, 417–18
- sulphoconjugation, 165
- sulphonamides, 157, 203, 414, 416–20  
 synthesis, 324–5
- sulphones, 160, 420
- sulphotransferases, 162, 165, 309, 682
- sultopride, 235
- sumatriptan, 205–6, 721, 740
- sunitinib, 557–9, 721, 740
- supercoiling, 74
- suppositories, 169
- Sur-2 protein, 140
- surface plasmon resonance, 197–8
- Sustanon 250, 727
- Sustiva, 727
- Sutent, 727
- suxamethonium, 589, 592, 721, 740
- Suzuki coupling, 325, 326
- sweat, 167
- Swern oxidation, 325, 326
- Sybyl, 338
- Symbicort, 727
- Symmetrel, 727
- sympathetic nervous system, 579
- Synagis, 727
- Synalar, 727
- Synalar C, 727
- Synalar N, 727
- synapses, 578–9
- synaptic button, 711
- synaptic gap, 711
- Synartis, 727
- Synercid, 457, 727
- synergism  
 antiviral agents, 477  
 dalfopristin and quinupristin, 456  
 herbal medicines, 212  
 of penicillins, 436  
 substituents, 243, 557
- synergistic effects, 231
- SYNOPSIS, 377–8
- Syntocinon, 727
- syphilis, 463  
 treatment of, 414, 454, 457

## T

- tabun, 600–1
- tacrine, 96, 404, 603–5, 721, 740
- Taft's steric factor, 391
- Tagamet, 660, 671, 727
- tagging, 329–31
- talampicillin, 434
- Tamiflu, 503, 505, 727
- tamoxifen, 115, 538, 540, 721, 740
- tarazosin, 621
- Tarceva, 727
- targeting drugs, 175, 191–2, 256–7, 263, 418  
 use of antibodies, 174–5, 257, 267, 568–73
- targeting viruses, 83
- targetin drugs with membrane tethers, 257–8
- Targocid, 727
- tariquidar, 523
- Tarivid, 727
- Tasigna, 727
- tautomers, 224
- Tavorole, 464
- Tavanic, 727
- taxoids, 137, 542
- Taxol, 137–8, 199, 289, 542, 566, 727
- Taxotere, 727
- tazobactam, 435, 445, 721, 740
- Tazocin, 445, 727
- tea, 2, 522
- Teflaro, 727
- teicoplanin, 257, 448–9, 451, 721
- Tekturna, 727
- telaprevir, 508–9, 721, 740
- Telfast, 727
- telithromycin, 456–7, 721, 740
- telomerase, 519, 564
- telomeres, 519
- Telzir, 728
- Temgesic, 728
- temocillin, 425, 431–2, 721, 740
- Temodal, 728
- Temodar, 728
- temoporfin, 574, 721, 740
- temozolomide, 127, 530, 721, 741
- temsirolimus, 285, 560, 721, 741
- teniposide, 122, 526–7, 721, 741
- tenofovir, 741

- tenofovir disoproxil, 478–9, 481, 721  
 Tenormin, 728  
 Tentagel resin, 315  
 teprotide, 202, 293–4  
 terazosin, 620, 721, 741  
 terfenadine, 166–7, 193  
 teriparatide, 266, 270  
 terphenyl structures, 142–3  
 testicular cancer, treatment of, 522, 525, 527, 530  
 testosterone, 537, 539  
 testosterone propionate, 537, 540, 721, 741  
 tetanus, treatment of, 423  
 tethers, 147  
 tetracycline, 741  
 tetracyclines, 414, 452, 454–5, 721  
 clinical aspects, 454, 462  
 interaction with calcium ions, 169  
*Pseudomonas aeruginosa* resistance, 426  
 resistance, 463  
 treatment of *Helicobacter pylori*, 685–6  
 tetrahydrofolate, 418–20, 531–2  
 tetrazole ring, bioisostere for carboxylic acid, 250–1  
 tetradotoxin, 201, 202  
 TGF, *see* transforming growth factor  
 TH-302, 528  
 thalassaemia, treatment of, 132  
 thalidomide, 196, 236, 275, 283, 565  
 thalidomide babies, 565  
 thebaine, 646, 653  
 theophylline, 673, 721, 741  
 therapeutic index, 2, 274, 414  
 therapeutic ratio, 274  
 therapeutic window, 171–2  
 thiaburimamide, 668–9  
 thienamycin, 442, 443  
 thio-dGTP, 536  
 thio-GMP, 536  
 thio-GTP, 536  
 thioguanine, *see* 6-thioguanine  
 thiols, binding role, 223  
 thiorphan, 653  
 thorn apple, 588  
 threonine, 705  
 phosphorylation, 60–1, 63, 65  
 thrombin, 44, 51  
 thrombospondin, 520  
 thymidine kinase, 472–3, 475, 573  
 thymidylate kinase, 472  
 thymidylate synthase, 407, 410, 531–3  
 inhibitors, 407–10, 532–4  
 thymidylate synthetase inhibitors, 473  
 thymine, 71–2  
 thyroid hormones, 55  
 thyroid problems, treatment of, 106  
 Tibotec, 494  
 ticarcillin, 426, 433, 435, 444, 721, 741  
 ticks, 468  
 tienilic acid, 94, 279–80  
 Timentin, 444, 728  
 Timodine, 728  
 timolol, 169, 623–5, 721, 741  
 timoprazole, 683  
 tioconazole, 249, 254, 721, 741  
 6-thioguanine, 534, 536, 721, 741  
 tipifarnib, 547, 721, 741  
 tipranavir, 204, 478, 492–4  
 tirofiban, 141–2, 721, 741  
 T-lymphocytes, 518  
 TNF, *see* tumour necrosis factor  
 TNP-470, 564  
 tobacco, 170, 582  
 tobacco smoke, 515  
 Tobi, 728  
 Tobradex, 728  
 tobramycin, 426, 718, 721, 741  
 toceranib, 560, 721, 741  
 Tofranil, 728  
 tolbutamide, 204, 209, 253  
 tolerance, 1–2, 114, 173, 266  
 Tomudex, 728  
 tonsillitis, treatment of, 423, 457  
 tooth abscesses, treatment of, 462  
 topiramate, 629, 720–1, 741  
 Topliss scheme, 394–7  
 topoisomerases, 74–6, 121–3, 459, 525–7, 540  
 poisons, 120–2, 524, 526–7  
 topomer methodology, 404  
 topotecan, 526–7, 721, 741  
 torcetrapib, 279  
 toremifene, 531–6, 538, 540, 721, 741  
 Torisel, 728  
*Torpedo marmorata*, 594  
 tositumomab, 569–70, 721  
 toxicity testing, 193, 274–5  
 toxins, action on enzymes, 96  
 Tozasertib, 555  
 TP53 gene, 515  
 Tracrium, 728  
 Trade Related Aspects of Intellectual Property Rights, 282  
 tramadol, 164  
 tranquilizers, 208  
 transcriptase, 469  
 transcription, 68, 77–8, 80  
 control of by drugs, 130–1  
 viruses, 469  
 transcription factors, 55, 67–8, 536, 564  
 agents affecting interactions with  
 coactivators, 139–40, 567  
 agents preventing DNA binding, 130–1  
 control of the estrogen receptor, 109–10  
 role in cancer, 519  
 role in the cell cycle, 517  
 transdermal absorption, 169  
 transduction, 463  
 transfer RNA, 76–7, 79–80  
 transferases, 36, 162, *see also* amino acid *N*-acyltransferase, arabinosyl transferase, catechol *O*-methyltransferase, chloramphenicol acetyltransferase, choline acetyltransferase, farnesyl transferase, geranylgeranyltransferase, glucuronyltransferase, glutathione *S*-transferase, guanyl transferase, methyltransferases, and sulphotransferase  
 transforming growth factor, 515–16  
 transforming growth factor receptor, 517  
 transgenic animals, 195–6, 268  
 transgenic plants, 268  
 transglycosidase, 445, 447  
 transglycosidation, 446  
 transition state, 30  
 transition-state analogues, 90–2, 183, 236, 296–7, 572  
 transition-state conformation, penicillins, 424  
 transition-state inhibitors, 91, 483, 498, 501–2, 535  
 transition-state intermediate, 297  
 transition-state isosteres, 236, 483–4, 535, 562  
 translation, 77–80, 452  
 translocase, 445  
 translocation, 78, 79  
 transpeptidase, 424–6, 428, 445, 447–8  
 inhibition by cephalosporin, 437  
 PBP2a, 441  
 transport proteins, 27–8, 259–60, 580, 613–14, 627, 701  
 as drug targets, 135–6  
 in drug absorption, 155  
 Transtec, 728  
 tranlycypromine, 629–30  
 Trasicor, 728  
 trastuzumab, 559, 569, 721  
 trauma, treatment of, 190, 624  
 traumatic memories, treatment of, 624  
 travellers' diarrhoea, treatment of, 459  
 Treanda, 728  
 recovirsen, 493–4  
 tretinoin, 566, 721, 741  
 triamcinolone, 690, 741  
 triamcinolone acetonide, 691–2, 721, 741  
 tricyclic antidepressants, 135, 189–90, 208, 627–8, 630, 700  
 tridihexethyl chloride, 589–90  
 trifluridine, 473–5  
 trihexyphenidyl, 589–90, 721, 741  
 trimethoprim, 419–20, 462, 721, 741  
 Trimopan, 728  
 Trimovate, 728  
 trinitroglycerine, 207–8  
 triplet code, 74, 77, 79  
 Tripos, 401, 405  
 tripotassium dicitratobismuthate, 686  
 Trisenox, 728  
 trisubstituted indanes  
 mimics for  $\alpha$ -helices, 270  
 peptidomimetic, 270  
 TRK-820, 655  
 tRNA, *see* transfer RNA  
 Trojan horse approach, 259–60  
 tropicamide, 589–90, 721, 741  
 Trosyl, 728  
 truth drug, 589  
 Truvada, 728  
 Trypanosomiasis, treatment of, 414, 465  
 tryptophan, 17, 22, 705  
 acetylcholinesterase enzyme, 596–7  
 reverse transcriptase, 479  
 safety-catch acid-labile linker, 329  
 serotonin receptor binding site, 344  
 transcription factor-cofactor interactions, 140

tuberculosis, 413–14  
 multidrug-resistant, 462  
 treatment of, 414, 451, 453, 461–2  
 tubocurarine, 2, 199, 353, 591  
 tubulin, 26–7, 135–7, 141, 405, 539–42  
 tubulin depolymerization, inhibition, 542–3  
 tubulin polymerization inhibitors, 404,  
 474–5, 540–2  
 tumour, 514  
 tumour necrosis factor receptors, 518  
 tumour necrosis factor-related apoptosis  
 inducing ligand, 566  
 tumour suppression genes, 515  
 tumour-necrosis factor, 268, 565  
 tumour-necrosis factor receptors, 518  
 $\beta$ -turn, 18, 20  
 Tykerb, 728  
 typhoid, 413  
 treatment of, 435, 454  
 tyramine, 616, 629–30  
 tyrosinase, 79  
 tyrosine, 17, 22, 611, 705  
 biosynthesis, 80  
 biosynthetic precursor, 611  
 endogenous opioids, 650–1  
 muscarinic receptor, 584  
 phosphorylation, 25, 37, 53–4, 63, 66  
 proton source in enzyme mechanism, 33  
 reverse transcriptase, 480  
 ribonucleotide reductase, 535  
 topoisomerase II, 75, 76  
 tyrosine hydroxylase, 564, 611–12, 626  
 inhibitor, 626  
 tyrosine kinase receptors, 54–5, 517–18,  
*see also* epidermal growth factor  
 receptor, growth hormone linked  
 receptor, insulin receptor, protein kinase  
 inhibitors  
 tyrosine kinases, 63, 66–8, 96, 514, 517–18, 548  
 tyrosine tRNA synthetase, 464  
 Tysabri, 728

## U

ubiquitin, 477, 563  
 UDFP-glucuronate, 162–3  
 UH-301, 236, 238  
 UK-46245, 233–4  
 UK-47265, 258, 275  
 UK-143220, 256  
 UK-157147, 256  
 ulcers, 659  
 treatment of, 212, *see also* antiulcer  
 agents  
 Ultralanum Plain, 728  
 Ultrasound, CNS access, 157  
 Ultravate, 728  
 Unasyn, 445  
 uncompetitive inhibitors, 90  
 Uniphyllin Continus, 728  
 uracil, 76, 235, 532–3  
 uracil mustard, 257, 527–8, 530  
 urease, 685  
 ureidopenicillins, 435–6  
 uremic pruritus, treatment of, 655

Uriben, 728  
 uridine triphosphate, 510  
 urinary tract infections, treatment of, 418,  
 432, 435, 442–3, 457–9, 461–2  
 urinary tract stimulation, 586  
 Uromitexan, 728  
 US National Cancer Institute, 137

## V

vaccinations, 413, 470  
 flu, 497  
 smallpox, 511  
 vaginosis, treatment of, 462  
 valaciclovir, 473, 475, 721, 741  
 Valcyte, 728  
 valdecoxib, 93, 95, 721, 741  
 Valentino, Rudolph, 659  
 valganciclovir, 473, 475, 721, 741  
 valine, 17, 22, 705  
 biosynthetic precursor for  $\beta$ -lactams,  
 422, 436  
 HIV-protease, 484, 489–90  
 HIV-protease inhibitors, 486, 489  
 HMG-CoA reductase, 183  
 in prodrugs, 434, 473, 475  
 Ras protein, 545  
 valinomycin, 146  
 valinomycin, 146–7, 414, 452  
 Valium, 172, 260–1, 728  
 Valtrex, 728  
 vampire, 574  
 van der Waals interactions, 8, 22  
 van Leeuwenhoek, 413  
 Vancocin, 728  
 vancomycin, 445–8, 451, 462, 721, 741  
 affinity screening, 197  
 dynamic combinatorial synthesis, 334  
 mechanism of action, 138–9, 446–7  
 source, 200, 446  
 vancomycin-resistant enterococci (VRE), 447  
 vancomycin-resistant *Enterococcus*  
*faecalis*, 462  
 vancomycin-resistant *Enterococcus*  
*faecium*, 457  
 vancomycin-resistant *Staphylococcus*  
*aureus*, 447  
 Vandetanib, 552, 559, 721, 741  
 vanillylmandelic acid, 612  
 Vansil, 728  
 Varenicline, 587, 721, 741  
 variation of alkyl substituents, 228–31, 249,  
 306, 638  
 variation of *N*-alkyl substituents, 250,  
 618, 638  
 variation of aromatic substituent  
 patterns, 306  
 variation of aromatic substituent positions,  
 229–31, 258, 308, 703  
 variation of aromatic substituents, 229–31,  
 250, 254–5, 258  
 design of oxamniquine, 305–8  
 serotonin antagonists, 703–4  
 variation of heterocyclic substituents, 684  
 variation of polar functional groups, 249  
 variation of polar substituents, 249  
 variation of pyridine substituents, 683  
 varicella-zoster virus, treatment of, 475  
 Vasce, 728  
 vascular endothelial growth factor, 143, 520,  
 561, 566, 569  
 vascular endothelial growth factor receptor  
 inhibition of kinase, 552  
 vasoactive intestinal peptide, 581  
 vasoconstrictors, *see* adrenaline, adrenergic  
 agonists, angiotensin II, clonidine,  
 noradrenaline  
 vasodilators, *see* adrenaline, adrenergic  
 antagonists,  $\beta$ -blockers, glyceryl  
 trinitrate, histamine, sildenafil  
 vasopressin, 23, 63, 700, 721  
 vasopressin receptors, 63  
 vasopressor, 617  
 vatalanib, 549, 558, 560  
 Veasnoide, 728  
 Veber's parameters, 155, 211, 319  
 Vectavir, 728  
 Vectibix, 728  
 vecuronium, 592–3, 721, 741  
 VEGF, *see* vascular endothelial growth  
 factor  
 vedotin, 569  
 Velbe, 728  
 Velcade, 728  
 vemurafenib, 556–7, 560, 721, 741  
 venlafaxine, 628, 721, 741  
 Ventmax, 728  
 Ventodisks, 728  
 Ventolin, 728  
 Vepesid, 728  
 verapamil, 523, 721, 741  
 Verloop steric parameters, 391  
 Vertex Pharmaceuticals, 491  
 vesicles, 614, 711  
 Viagra, 204, 208, 728  
 Vibramycin, 728  
 Victrelis, 728  
 vidarabine, 471, 473–5  
 Videx, 728  
 Vigamox, 728  
 vinblastine, 137, 208, 540, 543, 721, 741  
 Vinca alkaloids, 137, 543, 568  
 resistance, 523  
*Vinca rosea*, 540  
 vincristine, 137, 208, 540, 543, 566,  
 721, 741  
 vindesine, 137, 540, 543, 721, 741  
 vinorelbine, 137, 154, 540, 543, 721, 742  
 vinylloxycarbonyl chloride, 220, 223,  
 229, 639  
 VIOXX, 279, 728  
 Viracept, 728  
 Viraferon, 728  
 viral DNA polymerases, 129, 191, 472, 475  
 inhibitors, 472–5  
 viral gastroenteritis, 468  
 viral pneumonia, 468  
 viral RNA polymerase, 497  
 viral RNA-dependent RNA  
 polymerase, 510

Viramune, 728  
 Virazole, 728  
 Viread, 728  
 virion, 469–70  
 Virormone, 728  
 Virovir, 728  
 virtual screening, 198  
 virus vector, 573  
 viruses, 468  
   cause of cancer, 514  
   life cycles, *see* herpes simplex virus, HIV,  
     influenza virus  
   structure, 468–9, 476  
 Vismodegib, 556–7, 560, 721, 742  
 Vistamethasone, 728  
 Vistide, 728  
 vitamin K, 25, 454  
 Vitravene, 728  
 Volmax, 728  
 voltage-gated ion channels, 714  
 von Braun degradation, 639  
 Voraxaze, 728  
 vorinostat, 96, 564, 721, 742  
 Votrient, 728  
 VRSA, *see* vancomycin-resistant  
   *Staphylococcus aureus*  
 Vumon, 728  
 VX, 600–1  
 Vytorin, 184, 728  
 VZV, *see* varicella–zoster virus

## W

Walter Reed Army Institute of  
 Research, 300  
 Wang resin, 315–16  
 warfarin, 157, 166–7, 169, 204, 212, 280,  
 492, 673  
 Warticon, 728  
 Watson and Crick, 71, 224  
 weighted probe interaction energies, 404  
 Wellcome Trust, 189  
 whisky, 3  
 whooping cough, treatment of, 457  
 wild chervil, 540  
 willow tree, 202  
 Wilm's tumour, treatment of, 525  
 WIN-54954, 508  
 wine, 413  
 witches, 588  
 withdrawal symptoms, 114, 173, 266,  
 633, 643

World Health Organization, 413, 514, 700  
 World Trade Organisation, 282  
 wrenchnolol, 140–1

## X

Xalkori, 728  
 xamoterol, 205  
 xanomeline, 604  
 xanthine oxidase, 96, 473  
 Xeloda, 728  
*Xenopus laevis*, 201  
 Xifaxin, 728  
 Xolair, 728  
 Xopenex, 728  
 X-ray crystallography  
   acetylcholinesterase-inhibitor  
     complexes, 404  
   active conformations, 352–3  
   adrenergic receptors, 53, 367, 614  
   angiotensin–lisinopril complex, 296  
   bacteriorhodopsin and rhodopsin, 367  
   design of anticold agents, 508  
   design of HIV-protease inhibitors, 480,  
     482, 484–5, 487, 489, 491–2  
   design of kinase inhibitors, 551  
   design of neuraminidase inhibitors, 498,  
     501, 503, 505–6  
   design of NNRTIs, 479–80  
   drug design, 109, 207, 242, 269, 370, 407,  
     409, 410  
   fragment-based lead discovery, 210  
   HMG-CoA reductase, 183  
   pharmacophores, 355  
   protein–drug complexes, 215, 227–8,  
     241  
   protein kinases, 548  
   protein structure, 26, 242–3, 357  
   structural databases, 339, 353  
   structure determination, 212, 422, 436,  
     507, 633, 670  
 Xylocaine, 728  
 xylometazoline, 618

## Y

yeast alanine tRNA, 77  
 yellow fever, 468  
   treatment of, 470  
 Yentreve, 728  
 yew tree, 199, 289  
 yingzhaosu A, 304

## Z

Zactima, 728  
 zalcitabine, 478–9, 481, 721, 742  
 zanamivir, 345, 501–3, 506, 721, 742  
 Zantac, 676, 728  
 Zarnestra, 728  
 Zavedos, 728  
 ZD-9331, 534  
 Zeffix, 728  
 Zeftera/Zevtera, 729  
 Zelapar, 728  
 Zelboraf, 728  
 Zenapax, 729  
 Zerit, 729  
 Zestril, 729  
 Zetia, 729  
 Zevalin, 729  
 Ziagen, 729  
 ziconotide, 202  
 zidovudine, 95, 478–9, 481, 721, 742  
 zileutin, 96  
 Zinacef, 729  
 zinc cofactor, 564  
 zinc finger domains, 56  
 zinc ions  
   cofactors, 35, *see also* zinc  
     metalloproteinases  
   intracellular receptors, 56  
   ligands, 221, 223, 546, 562, 564  
 zinc metalloenzyme, 544  
 zinc metalloproteinases, 221, 292  
 Zinnat, 729  
 Zispin, 729  
 Zithromax, 729  
 Zocor, 729  
 Zofran, 729  
 Zoladex, 729  
 Zolinza, 729  
 Zomorph, 729  
 zoonoses, 468  
 Zortress, 729  
 zosuquidar, 523  
 Zosyn, 445, 729  
 Zoton, 729  
 Zovirax, 729  
 Zulus, 541  
 Zyban, 204, 629, 729  
 Zyloric, 729  
 Zyprexa, 729  
 Zytiga, 729  
 Zyvox, 729